How many investments has RA Capital made?

RA Capital has 353 tracked investments, 102 of which have exited, including 53 dated in the last 24 months.

What stage does RA Capital invest at?

RA Capital invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.

What sectors does RA Capital focus on?

RA Capital focuses on Biotech, Climate Tech, Digital Health, Healthtech, Medical Devices.

Where is RA Capital located?

RA Capital is headquartered in Boston, US.

Does RA Capital lead rounds?

RA Capital has led 24 of the 65 rounds where its role is on record.

Who does RA Capital co-invest with?

RA Capital most often shares deals with Foresite Capital, OrbiMed, Bain Capital Life Sciences, among 256 tracked co-investors.

What size deals does RA Capital back?

Across 27 deals with disclosed amounts, RA Capital has joined rounds of $7.9M – $325M (median $100M).

RA Capital

Crossover fundActively deploying

Boston · Seed–Late Stage · 86 people tracked

Also known as RA CAPITAL MANAGEMENT, LP · RA Capital Nexus · RA Capital Nexus International · RA Capital Planetary Health · RA Capital Planetary Health International

★ Follow + Add to CRM ⤳ Find an introduction

Find your way into RA Capital

2,561 people in our graph share verified history with the RA Capital team — schools, employers, funds. One of them is your warm intro.

Kyle Dohertyunlockedknows Jake Simson · together at Massachusetts Institute of Technology (overlapped)

knows the team · via Yale University

×2knows the team · via Harvard University

×2knows the team · via Massachusetts Institute of Technology

×2knows the team · via Cornell

knows the team · via College of the Holy Cross

✨ Fox Verdict

Investment thesis

RA Capital pursues evidence-based, full-lifecycle investing across healthcare, life sciences, and planetary health. It provides multi-stage capital spanning private and public markets, from new company creation and seed-stage incubation through venture rounds, crossover financing, IPO, and later-stage public investing. The firm emphasizes deep landscape research, scientific diligence, and operational company-building support, backed by a team of over 200 people with scientific and operational depth. In healthcare it partners early to shape strategy and define proof points, then provides capital continuity through growth. Its planetary health arm targets near-market, scalable companies advancing resource availability, energy innovation, and industrial productivity. Its Raven platform incubates and co-creates companies to address unmet biomedical needs.

Invests inBiotech Climate Tech Digital Health Healthtech Medical Devices Boston Europe United States

Source: firm website, verified Sep 22, 2026.

Stage

Seed–Late Stage

Boston, Massachusetts, US

Instruments

Equity

Founded

2004

Last 12 months

37 investments

AUM

$16.4B

Tracked investments

353

Unicorns

IPOs

Acquisitions

Team · 86 people

from the firm's website & curated & public directories

Brigid O’Brien· Managing Partner

Kyle Teamey· Managing Partner· Greater Bostonin

Brigid O'Brien· General Partner· Boston, Massachusetts, United Statesin

Peter Kolchinsky· Managing Partner· Boston, Massachusettsin 𝕏

p•••@racap.comreveal

Rajeev Shah· Managing Partner· Boston, Massachusettsin

Adam Kaye· Senior Managing Director and Partner, Structured Capital· Zürich Metropolitan Areain

Adam Kaye is Senior Managing Director and Partner, Structured Capital at RA Capital Management. He has more than 20 years of experience in finance and investment, with a focus on structured capital solutions for the healthcare and life sciences sectors.

Jeremy Lack· Partner

Josh Resnick· Partner· Boston, Massachusetts, United Statesin

Matt Hammond· Partner· Barcelona, Catalonia, Spainin

Derek DiRocco· Partner· Boston, Massachusettsin

Jake Simson· Partner· Cambridge, Massachusettsin

Laura Stoppel· Partner· Somerville, Massachusettsin

Reza Halse· Partner· Cambridge, Massachusetts𝕏

Zach Scheiner· Partner· Boston, Massachusettsin

Emory Werner· Investment Director, Venture· New York, New York, United Statesin

Jonathan Pritz· Investment Director, Venture· Boston, Massachusetts, United Statesin

Kathryn Meng· Principal· Boston, Massachusetts, United Statesin

Kathryn Meng is a Principal at RA Capital Management, where she invests in companies across energy, industrial decarbonization, critical minerals and metals, agtech, and biotech, including Bia Energy, Koloma, AM Batteries, Avalanche Energy, Optivolt, Reframe Systems, and Sortera Technologies. She previously served as SVP of Strategy at Energetic Insurance, led partnerships, advocacy, policy, and carbon technology work at Indigo Ag, and worked as an Investment Principal at the Massachusetts Clean Energy Center, managing a portfolio spanning renewables, mobility, industrial efficiency, sustainable buildings, grid resilience, and the water-energy nexus.

Laura Tadvalkar· Managing Director, Venture· Boston, Massachusetts, United Statesin

Megan Lipcsey· Investment Director

Tess Cameron· Managing Director, Venture· Cambridge, Massachusetts, United Statesin

Alyssa Larson· Director, Investor Relations· Boston, Massachusettsin

Anurag Kondapalli· Principal· New York, New Yorkin

Anurag Kondapalli is a Principal on the investment team at RA Capital Management, where he works on public and private investments across healthcare, technology, and services. He previously served as Vice President in Structured Growth Capital and Royalty Opportunities at OrbiMed Advisors, handling deal sourcing, diligence, negotiation, and valuation for growth-stage companies. He holds a BSE in Biomedical Engineering and a BS in Economics from Duke University and joined RA Capital in 2021.

Emily Minkow· Managing Director, Venture· New York, New Yorkin

Jenna Hebert· Investment Director· Boston, Massachusettsin 𝕏

Monica Stanciu· Director, TechAtlas· United Statesin

Monica Stanciu is a Director at RA Capital Management, where she leads strategic and diligence initiatives within the TechAtlas division and supervises associate workflow and development. She holds a PhD in Cancer Biology from MIT, with doctoral research focused on epigenetic regulators in glioblastoma.

Nandita Shangari· Managing Director, Venture· United Statesin

Adrian Bot· Venture Partner

Anish Suri· Consulting Venture Partner

Bimal Shah· Venture Partner

Cosmas Giallourakis· Venture Partner - Consultant· Cambridge, Massachusetts, United Statesin

David Weinstock· Venture Partner

Fanny Cavalié· Venture Partner

Gerald Sewack· Venture Partner· Boston, Massachusetts, United Statesin

Jacob Oppenheim· Venture Partner

Jill Wykosky· Venture Partner· Greater Bostonin

Jill Wykosky is a Venture Partner at Raven (RA Ventures). She previously spent eleven years at Takeda Pharmaceuticals, where she served as Head of Neurogastroenterology Research and built a biology and pharmacology team within the Gastroenterology Drug Discovery Unit, overseeing preclinical discovery work across sites in San Diego, CA and Cambridge, MA. Her drug discovery experience spans small molecule, peptide, antibody, and cell therapy modalities, and she holds a B.S. in Microbiology from the University of Pittsburgh and a Ph.D. in Molecular Medicine from Wake Forest University School of Medicine, followed by a post-doctoral fellowship at the Ludwig Institute for Cancer Research San Diego Branch.

Mario Barro· Venture Partner· Vienna, Virginia, United Statesin

Mario Barro is a Venture Partner and Head of Infectious Diseases at RA Capital, where he focuses on early-stage investment and company creation and serves as a board member or technical advisor for several portfolio companies. He is President and CEO of GIVAX, Inc., a company developing rotavirus-norovirus pediatric vaccines. His earlier career includes roles as Associate Vice President for Advanced Research at Sanofi Pasteur and Project Director at BARDA, where he oversaw the Universal Flu Vaccine project, along with postdoctoral training at NIH and Mount Sinai School of Medicine.

Milind Deshpande· Venture Partner

Nithya Desikan· Venture Partner

Paul Rothman· Venture Partner

Paul Yaworsky· Venture Partner· Greater Bostonin

Ramin Farzaneh-Far· Venture Partner· United Statesin 𝕏

Ramin Farzaneh-Far is a Venture Partner at RA Ventures (Raven). His areas of work include the design, implementation, and interpretation of clinical trials across early (Phase I-II) and late (Phase III-IV) development, as well as translational research, business development, and corporate strategy.

Robert Nicol· Venture Partner

Charlie Wilson· Venture Partner and Head of Infectious Diseases at RA Capital· Washington, District of Columbia, United Statesin

Charlie Wilson joined Paladin Capital Group in 2026 as its first Director of AI and Data Analytics, leading the development of AI and analytics tools for investment research, portfolio monitoring, and internal operations. He previously spent thirteen years at Thornburg Investment Management, where he served as Managing Director and Portfolio Manager for emerging markets and international equity strategies and, from 2019 to 2021, as the firm's first Director of Research, and earlier was a Partner and Senior Equity Analyst at Marsico Capital Management. He holds a Ph.D. in Geophysics from the University of Colorado Boulder and a B.S. in Geology from the University of Arizona, completed postdoctoral research at Stanford and Columbia's Lamont-Doherty Earth Observatory, and is finishing an M.S. in Analytics at Georgia Tech.

Chris Sutherland· Venture Partner· Canadain

Abigail Schmitz· Senior Associate, Corporate Development· New York, New York, United Statesin

Abigail Schmitz is a Senior Associate in Venture and Corporate Development at RA Capital Management, working in the healthcare sector. She earned a Ph.D. from the Hubbell Laboratory at the University of Chicago and holds a degree in Chemical Engineering with a minor in Mandarin from the University of Alabama.

Albert Kim· Advisor

Alex Miller· Senior Associate, Venture· Cambridge, Massachusetts, United Statesin

Alex Zhang· Vice President, Structured Capital· New York, New York, United Statesin

Alex Zhang is a Vice President in Structured Capital, Healthcare at RA Capital Management, where the focus is on credit investing in the healthcare sector. Zhang holds a JD in Law and an MBA in Healthcare Management from Penn Law and Wharton, and a BSc from NYU Stern with concentrations in Finance and Statistics.

Alison Tisdale· Advisor

Breanna O’Reilly· Analyst

Dan Grau· Advisor

David Feltquate· Advisor· Toronto, Ontario, Canadain

Davis Buchanan· Associate, Structured Capital· New York, New York, United Statesin

Eric Wei· Associate, Structured Capital· Boston, Massachusetts, United Statesin

Henry Stusnick· Analyst· Boston, Massachusetts, United Statesin

Jaclyn Henderson· Advisor· Cambridge, Massachusetts, United Statesin

Jaclyn Henderson is an Entrepreneur in Residence at RA Ventures and VP of Early Discovery at Neuro StealthCo, with over 14 years of experience in small molecule drug discovery. Her background is in medicinal chemistry, spanning neurodegeneration and psychotherapeutics work on targets including LRRK2, TTBK1, GBA, and various GPCR and SLC projects, and she has previously held roles at Biogen, Pfizer, and Jnana Therapeutics. She is a co-inventor of three clinical-stage assets, including Tavapadon, a D1 agonist in Phase 3 trials for Parkinson's disease.

Joel Barrish· Advisor

Jonathan Hill· Entrepreneur-In-Residence· Boston, Massachusetts, United Statesin

Julie Gupta· Senior Associate, Corporate Development, Venture· Greater Bostonin

Justin Waney· Vice President, Structured Capital· New York, New York, United Statesin

Kurt Armbrust· Entrepreneur in Residence

Matt Stanton· Advisor

Michael Rosenzweig· Advisor

Michael Sherman· Advisor

Mike Cloonan· Advisor

Neil Buckley· Advisor

Pat Schnettler· Senior Associate· Greater Bostonin

Patrick Trojer· Advisor

Prithviraj Singha Roy· Analyst· Greater Bostonin

Richard Xie· Senior Health Economist· Boston, Massachusetts, United Statesin

Richard Xie is a health economist and policy analyst serving as Senior Economic and Policy Advisor at No Patient Left Behind. His work applies quantitative and qualitative research methods to public health policy and to the commercialization of pharmaceutical products.

Sadik Kassim· Advisor

Sahiba Baveja· Associate, Structured Capital· New York, New York, United Statesin

Sahiba Baveja is a Structured Capital Associate at RA Capital Management, a healthcare-focused hedge fund. Her work centers on structured capital investing in the healthcare and life sciences sectors.

Sophie Papa· Advisor

Tyler Carney· Associate, Structured Capital· New York City Metropolitan Areain

Michael Saulnier· Director· Greater Bostonin

Sinead Wagner· Director

Tammy Seymour· Director

Yann-Eric N'Cho· Associatein

Andrew Levin· Advisor

Andrew Levin is an Advisor with the investment team at RA Capital Management, where he previously held the roles of Partner and Managing Director. Before joining RA Capital, he was a Vice President at H.I.G. BioVentures and Director of Pharmaceutical Sciences at the Clinton Health Access Initiative. He earned a BSE in Mechanical Engineering from Princeton University, a PhD in Biomedical Engineering from MIT, and an MD from Harvard Medical School.

Daniel Bahcheli· Boston, Massachusettsin 𝕏

Daniel Bahcheli is a Director at RA Capital Management, L.P. He has over 10 years of experience as a medical and science writer and editor, with expertise in oncology and hematology communications.

Fuad Naser· Analyst· Boston, Massachusettsin

Fuad Naser is an Analyst on the investment team at RA Capital Management, working on public and private investments within the Healthcare, Technology, and Services team. He focuses on companies developing and commercializing medical devices, diagnostics, and life science research tools. Before RA Capital, he was a Fellow at Flagship Pioneering, and he holds a BA in Biology and a PhD in Biological Chemistry from Washington University in St. Louis.

Habib Dable· Advisor· Cambridge, Massachusettsin

Habib Dable is an Advisor at Raven, where he advises and supports new companies, portfolio companies, and executives. He previously spent five years as President and CEO of Acceleron Pharma, which was acquired by Merck in 2021, and earlier held leadership roles over roughly 22 years at Bayer AG, including President, U.S. Pharmaceuticals. He holds a BBA and MBA from the University of New Brunswick and completed executive programs at Stanford University and Korn/Ferry.

Maxwell DeNies· Analyst· Boston, Massachusettsin

Maxwell DeNies is an Analyst on the investment team at RA Capital Management, where he conducts due diligence on biotechnology companies and advises portfolio companies on program and pipeline strategy. He holds a BS in Biology from the State University of New York at Fredonia and a PhD in Cellular and Molecular Biology from the University of Michigan. He joined RA Capital in 2020.

Nathan Davis· Analyst· Boston, Massachusettsin

Nathan Davis is a co-founder at StudioDx. He has work experience in venture capital and investment banking, with expertise in due diligence, life sciences, mergers and acquisitions, and financial modeling. Davis holds a Bachelor of Science in Cell Biology with a minor in Mathematics from the University of Vermont.

Peter Balogh· Analyst· Boston, Massachusettsin

Shan Shan Wang· Associate Director, TechAtlas· Boston, Massachusettsin

Shan Shan Wang is an Associate Director on the TechAtlas team at RA Capital Management, where she leads internal and external strategic and diligence work and oversees the workflow and development of TechAtlas Associates. She previously worked as a Senior Associate covering areas including Orphan Heme, Orphan GOF, vaccines, and gene therapies. She holds a BS in Brain and Cognitive Sciences from MIT and a PhD in Neuroscience from Harvard University.

Founder mafia

The RA Capital mafia →

7 people who came through RA Capital went on to found or lead other companies.

Josh ResnickPartnerFounded Synolo Therapeutics +3 Adam CottonConsultantFounded Epi Biologics Emily MinkowManaging Director, VentureFounded Stylus Medicine Mario BarroVenture PartnerFounded GIVAX Patrick TrojerAdvisorFounded Triana Bio Risa StackEntrepreneur In ResidenceFounded menlomicro-bg James McArthurVenture PartnerFounded PepGen

What they invest in

from 257 of 353 portfolio companies

Biotech ×213Healthtech ×131Medical Devices ×83Deep Tech ×28Digital Health ×28AI & Machine Learning ×22Cleantech ×7Climate Tech ×6

HQs:United States×195United Kingdom×4Denmark×3Switzerland×2China×2Germany×2

Who they back

founder profiles across 99 portfolio companies

44%

solo founders

44 of 99 mapped founding teams

32%

repeat founders

of 85 founders with career history

~4 yrs

old at investment

median across 59 dated deals

Founding team size:solo founder×442 founders×363 founders×144+ founders×5

Where their founders studiedfrom 75 founders with education data

Massachusetts Institute of Technology ×9Harvard Business School ×5University of California, Berkeley ×5Stanford University ×4Dartmouth College ×3Harvard University ×3Heidelberg University ×3Stanford University School of Medicine ×3

What their founders studiedfrom 75 founders with field-of-study data

Life Sciences ×35Engineering ×16Business & Management ×12Medicine ×11Chemistry ×10Computer Science ×10Finance & Accounting ×7Physics ×6

Where their founders worked beforefrom 85 founders with career history

MPM BioImpact ×5Harvard Medical School ×4Johnson & Johnson ×4Celsius Therapeutics ×2ClarVista Medical ×2Curie.Bio ×2ETH Zurich ×2iRobot ×2

Accelerator rootsportfolio companies that came through a program

Y Combinator ×2

46 founders hold a PhD · 13 hold an MBA (of 77 with degree data)

Investments · 353 tracked

founders shown can be your intro path

By year:2026 · 27 2025 · 21 2024 · 19 2023 · 7 2022 · 12 2021 · 25 2020 · 13 2019 · 7 2018 · 7 2017 · 4 2016 · 4 2015 · 8157 dated

Freenomefreenome.com in 𝕏NASDAQ: FRNMSeries B · Oct 2015 · $160M✓ verified

Freenome develops early-stage cancer detection technology using blood tests to identify cancer in its earliest, most treatable phases.

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesLondon

Riley Ennis(Co-Founder and Chief Product Officer)inCharles Roberts(Director)inGabriel Otte(Director)inAdam Stone(Chief Executive Officer and Director)Michael Altman(Chief Business Officer and Director)Shmuel (Sam) M. Cohn(Chief Financial Officer)

Co-investorsAgent Capital AME Cloud Ventures Andreessen Horowitz Artis Ventures Asset Management Company Averin Capital +9 more

Sionnatxsionnatx.com in 𝕏NASDAQ: SION✓ verified

Sionna Therapeutics is a biopharmaceutical company founded in 2019 that develops small-molecule therapies for cystic fibrosis by targeting and stabilizing NBD1, the domain of the CFTR protein where the common ΔF508 mutation occurs.

BiotechHealthtechMedical Devices

Greg(Co-founder & Senior Vice President of Discovery Research)Mark(Co-founder & Senior Vice President of Medicinal Chemistry)Mike(President & CEO)Charlotte(Chief Medical Officer)Elena(Chief Financial Officer)Caroline(Chief Business Officer)

Co-investorsAtlas Venture OrbiMed

Mineralys Therapeuticsmineralystx.com in 𝕏NASDAQ: MLYSJun 2022

Mineralys Therapeutics is a clinical-stage pharmaceutical company developing lorundrostat, a treatment targeting dysregulated aldosterone.

BiotechHealthtechRadnor, US

Eric Warren(Chief Commercial Officer)in Alex Gold(Chief Medical Officer)inAdam Levy(Executive Officer)Alexander Asam(Director)

BoardBrian Taylor Slingsby(Founder & former CEO / Board Director)Olivier Litzka(Director)in

Board seat Derek DiRocco· per SEC Form D

Co-investorsAndera Partners Samsara BioCapital SR One Capital Management Ysios Capital Adams Street Partners Boulder Ventures +1 more

Spero Therapeuticssperotherapeutics.com inNASDAQ: SPROMar 2017

Spero Therapeutics is a clinical-stage biopharmaceutical company developing medicines for immune-mediated diseases, led by SP001, a third-generation anti-CD40L antibody targeting IgG4-related disease.

BiotechCambridge, US

Ankit Mahadevia(Executive Officer, Director)in Stephen Garbacz(Executive Officer)inEsther Rajavelu(Director, President, Chief Executive Officer, Chief Financial Officer, Chief Business Officer and Treasurer)in

Board Jean-Francois Formela(Director)inCasper Breum(Director)

Board seatReza Halse· per SEC Form D

Co-investorsHEALTHCARE ROYALTY PARTNERS MRL Ventures Fund OUP (Osage University Partners)Alphabet Atlas Venture Fidelity Investments

Wave Life Scienceswavelifesciences.com in 𝕏NASDAQ: WVEJan 2015

Wave Life Sciences develops RNA-targeting therapeutics using RNA-editing modalities and chemistry to treat rare and common diseases, with a clinical pipeline addressing Alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, Huntington's disease, and obesity.

BiotechHealthtechLongevitySingapore

Takeshi Wada(Director)inGregory L. Verdine(Director)Paul B. Bolno, M.D.(Executive Officer, Director)in

BoardKen Takanashi(Director)Masaharu Tanaka(Director)

Board seat Peter Kolchinsky· per SEC Form D

Co-investorsForesite Capital

Aclaris Therapeuticsaclaristx.comNASDAQ: ACRS

Aclaris develops investigational monoclonal antibodies and small-molecule inhibitors targeting immune pathways for the treatment of atopic, autoimmune, and respiratory diseases.

BiotechHealthtechMedical DevicesWayne, US

Neal Walker(Executive Officer, Director)Kamil Ali-Jackson(Executive Officer)Stuart D. Shanler(Executive Officer)inJoseph Monahan(Executive Officer)in Hugh Davis(Executive Officer, Director)inJames Loerop(Executive Officer)

Co-investorsAisling Capital APERTURE Venture Partners F-Prime Capital Foresite Capital Sofinnova Ventures Sofinnova Venture Partners +1 more

Adagio Medicaladagiomedical.comNASDAQ: ADGM

Adagio Medical develops and commercializes catheter-based cardiac ablation devices using proprietary Ultra-Low Temperature Ablation (ULTA) technology to treat ventricular tachycardia and other cardiac arrhythmias.

HealthtechLaguna Hills, US

Olav Bergheim(Executive Officer, Director)Andrew Wade(Executive Officer)Hugh Neuharth(Executive Officer)Todd Usen(Chief Executive Officer and Director)inDeborah Kaster(Chief Financial Officer and Chief Business Officer)in

BoardMichael Zhao(Director)

Adagio Medical HoldingsNASDAQ: ADGMOct 2025

Adagio Medical Holdings develops and commercializes catheter-based ablation devices using proprietary Ultra-Low Temperature Ablation technology to treat ventricular tachycardia, a life-threatening abnormal heart rhythm, primarily in patients with structural heart disease.

HealthtechLaguna Hills, US

Todd Usen(Executive Officer, Director)inDeborah Kaster(Executive Officer)in

BoardKeyvan Mirsaeedi-Farahani(Director)Orly Mishan(Director)James L. Cox(Director)Timothy P. Moran(Director)

Adagio TherapeuticsNASDAQ: IVVDApr 2021 · $336M

Invivyd develops monoclonal antibody therapies to prevent and treat serious viral infections, beginning with COVID-19 and expanding to respiratory syncytial virus and measles.

BiotechWaltham, US

Tillman U. Gerngross(Executive Officer, Director)Lynn Connolly(Executive Officer)Eric Kimble(Executive Officer)inHalley Gilbert(Executive Officer)Rebecca Dabora(Executive Officer)inEllie Hershberger(Executive Officer)

Co-investorsFidelity Investments Foresite Capital GV (Google Ventures)MITHRIL Mithril Capital Management OrbiMed +3 more

Aeglea Biotherapeutics inNASDAQ: SYREacquired by Spyre Therapeutics · Nov 2023

Spyre Therapeutics develops monoclonal antibodies with extended half-lives targeting inflammatory bowel disease and rheumatic conditions including rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis.

BiotechAustin, US

David G. Lowe(Executive Officer, Director)George Georgiou(Director)Charles N. York(Executive Officer)inCameron Turtle(Chief Executive Officer and Director)

BoardHenry Skinner(Director)Armen Shanafelt(Director)

Agenusagenusbio.comNASDAQ: AGENAug 2026

Agenus is a biotechnology company developing cancer immunotherapies, including its lead investigational combination of botensilimab (an anti-CTLA-4 antibody) and balstilimab (a PD-1 inhibitor), known as BOT+BAL.

BiotechHealthtechLexington, US

Garo Armen(Chairman & CEO, Co-founder)Ozer Baysal(Executive Officer)Robert Stein(Executive Officer)Christine Klaskin(Executive Officer)inKaren Valentine(Executive Officer)Steven O'Day(Chief Medical Officer)in

Co-investorsAdvent Life Sciences Grazia Equity GmbH HEALTHCARE ROYALTY PARTNERS Oberland Capital Commodore Capital Invus +1 more

Aktis Oncologyaktisoncology.com inNASDAQ: AKTSSep 2024 · $318M

Aktis Oncology discovers and develops targeted radiopharmaceuticals for treating solid tumors.

BiotechHealthtechMedical DevicesBoston, US

Todd Foley(Co-founder and Chairman)in Patrick Baeuerle(Co-founder & Advisor)inShulamit Ron-Bigger(Executive Officer)inKyle D. Kuvalanka(Chief Financial Officer)inAkos Czibere(Chief Medical Officer)in Paul L. Feldman(Chief Scientific Officer)in

Co-investorsAndreessen Horowitz EcoR1 Capital MPM BioImpact MRL Ventures Fund Pappas Capital TCG Crossover +5 more

AN2 Therapeuticsan2therapeutics.com inNASDAQ: ANTXMar 2026

AN2 Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule drugs from its boron chemistry platform, with a pipeline spanning hematologic diseases, infectious diseases, oncology, and bone disorders.

BiotechHealthtechMenlo Park, US

Joseph S. Zakrzewski(Co-Founder & Director)Eric Easom(Co-Founder, President & CEO)inGeorge H. Talbot(Co-Founder & Senior Clinical Advisor)Michael R.K. (Dickon) Alley(Co-Founder, SVP Research Fellow, Head of Biology)Sanjay Chanda(Chief Development Officer)in Lucy O. Day(Chief Financial Officer)in

Co-investorsAdjuvant Capital BioRock Ventures Flucas Ventures Mountain Group Capital Biotechnology Value Fund Hatteras Venture Partners

Apogee Therapeuticsapogeetherapeutics.com inNASDAQ: APGE

Apogee Therapeutics develops engineered antibody therapies to treat inflammatory and immune diseases with reduced injection frequency compared to existing treatments.

BiotechHealthtechMedical Devices

Michael Henderson(Chief Executive Officer and Director)in

Co-investorsAccess Biotechnology Blackstone Life Sciences Perceptive Xontogeny Venture RTW Investments L.P.Venrock Healthcare Capital Partners

Arcutisarcutis.com in 𝕏NASDAQ: ARQTOct 2019

Arcutis is a biopharmaceutical company focused on dermatology, developing treatments for immune-mediated skin diseases such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis, and scalp psoriasis.

BiotechHealthtechMedical DevicesWestlake Village, US

Todd Franklin Watanabe(Executive Officer, Director)Alexander Asam(Director)Ricky Sun(Director)

Board Patrick Heron(Director)in Daniel Estes(Director)inJonathan Silverstein(Director)

Co-investorsBain Capital Life Sciences Frazier Life Sciences

Arvinas Holding Co. LLCarvinas.com in 𝕏NASDAQ: ARVN

Arvinas is a biopharmaceutical company developing PROTAC protein degrader therapies, with a pipeline focused on oncology and neurology.

BiotechHealthtechNew Haven, US

Sean Cassidy(Executive Officer)in Manuel Litchman(Executive Officer, Director)in Randy Teel(President and Chief Executive Officer; Director)in

BoardStephen Squinto(Director)in Liam Ratcliffe(Director)in Tim Shannon(Director)in

Co-investors5AM Ventures Access Biotechnology Canaan Partners Connecticut Innovations Nextech Invest Solasta Ventures +1 more

Atea Pharmaceuticalsateapharma.comNASDAQ: AVIR

Atea is a clinical-stage biopharmaceutical company developing oral direct-acting antiviral therapies for single-stranded RNA viruses, currently focused on a bemnifosbuvir and ruzasvir regimen in Phase 3 development for hepatitis C virus (HCV).

BiotechHealthtechBoston, US

Jean-Pierre Sommadossi, Ph.D.(Executive Officer, Director)Jean-Pierre Sommadossi(President, CEO and Chairman of the Board)inAndrea Corcoran(Chief Financial Officer, Executive Vice President, Legal, and Secretary)Janet Hammond(Chief Development Officer)inMaria Arantxa Horga(Chief Medical Officer)inJohn Vavricka(Chief Commercial Officer)in

Co-investorsBain Capital Life Sciences

Bicara Therapeuticsbicara.com in 𝕏NASDAQ: BCAX

Bicara Therapeutics is a clinical-stage biopharmaceutical company developing bifunctional antibody therapies that combine tumor-targeting with immune-modulating payloads to treat solid tumors.

Ivan Hyep(Chief Financial Officer and Treasurer)inLara Meisner(Chief Legal Officer, Compliance Officer and Corporate Secretary)in David Raben(Chief Medical Officer)in

Co-investorsAisling Capital Eight Roads Ventures F-Prime Capital Foresite Capital Premji Invest Red Tree Venture +5 more

BioAge Labsbioagelabs.com in 𝕏NASDAQ: BIOAFeb 2024

BIOAGE develops therapies targeting the molecular pathways that drive aging to increase healthspan and address age-related chronic diseases.

BiotechHealthtechLongevityRichmond, US

Kristen Fortney, PhD(Co-Founder, CEO)Eric Morgen, MD(Co-Founder, COO)Kristen Fortney(Executive Officer, Director)in Eric Morgen(Director)inDov Goldstein(Executive Officer)in

Board Patrick Enright(Director)in

Co-investorsAndreessen Horowitz Elad Gil Felicis Ventures IA Seed Ventures Longitude Capital OrbiMed +5 more

Biohavenbiohaven.com in 𝕏NYSE: BHVN

Biohaven is a pharmaceutical company that discovers, develops, and commercializes medications for neurological and neuropsychiatric diseases, including epilepsy, pain, mood disorders, OCD, spinocerebellar ataxia, and spinal muscular atrophy.

BiotechHealthtechMedical DevicesConnecticut, US

Vlad Coric, M.D.(Chairman & Chief Executive Officer)in

Co-investorsOberland Capital Sixth Street BlackRock

Black Diamond Therapeutics, Incblackdiamondtherapeutics.comNASDAQ: BDTX

Black Diamond Therapeutics develops small-molecule kinase inhibitors targeting families of oncogenic mutations across cancer types, including its lead candidate silevertinib for EGFR-mutant lung cancer and glioblastoma.

Elizabeth Buck(Chief Scientific Officer)inBrent Hatzis-Schoch(Chief Operating Officer and General Counsel)inSergey Yurasov(Chief Medical Officer)inMelanie Morrison(Chief Development Officer)

Co-investorsLAV Lilly Asia Ventures New Enterprise Associates (NEA)Nextech Invest NSG Ventures Versant Ventures +3 more

Bolt Biotherapeuticsboltbio.com in 𝕏NASDAQ: BOLT

Bolt Biotherapeutics is a clinical-stage biotech company developing novel immunotherapies that leverage innate immune system mechanisms to treat cancer.

BiotechHealthtechMedical DevicesSan Francisco, US

Dr. Edgar G. Engleman(Founder)

Co-investorsPfizer Venture Investments Samsara BioCapital Sofinnova Ventures Vivo Capital Nan Fung Life Sciences Novo Holdings +3 more

Boundless Bioboundlessbio.com in 𝕏NASDAQ: BOLD

Boundless Bio develops precision oncology medicines targeting ecDNA-amplified cancers, specifically creating a new category of ecDNA-directed therapies for patients with oncogenic alterations.

BiotechMedical DevicesLa Jolla, US

Zachary D. Hornby(Executive Officer, Director)in Robert Doebele(Chief Medical Officer)inChristian Hassig(Chief Scientific Officer)Jessica Oien(Chief Legal Officer and Corporate Secretary)in

BoardBenjamin Cravatt, Ph.D.(Director)Kristina Burow(Director)in

Co-investorsARCH Venture Partners Nextech Invest NEXTECH ONCOLOGY SCSP SignalFire

C4 Therapeuticsc4therapeutics.com in 𝕏NASDAQ: CCCCDec 2015

C4 Therapeutics develops targeted protein degradation medicines aimed at treating disease.

BiotechCambridge, US

Kenneth C. Anderson(Director)Andrew J. Hirsch(Director and Chief Executive Officer)in

BoardMarc Cohen(Executive Officer, Director)inJason Fisherman(Executive Officer, Director)Miles Stuchin(Director)Bruce Downey(Director)

Co-investors3E Bioventures Capital Bain Capital Life Sciences Nextech Invest Cobro Ventures

Century Therapeutics, Inc.centurytx.com inNASDAQ: IPSCFeb 2021

Century Therapeutics develops allogeneic, iPSC-derived cell therapies using gene editing and protein engineering for autoimmune diseases including type 1 diabetes and cancer.

AI & Machine LearningBiotechHealthtechMedical DevicesPhiladelphia, US

Osvaldo Flores, Ph.D.(Executive Officer, Director)Douglas Carr(Executive Officer)in Brent Pfeiffenberger(President and Chief Executive Officer)inGregory Russotti(Chief Technology and Manufacturing Officer)Chad Cowan(Chief Scientific Officer)in

BoardToshikazu Ban(Director)

Co-investorsCasdin Capital Versant Ventures

Ceribellceribell.com in 𝕏NASDAQ: CBLL

Ceribell is a medical technology company that develops products for detecting and monitoring seizures, including EEG-based diagnostic systems.

AI & Machine LearningDigital HealthHealthtechMedical DevicesSunnyvale, US

Josef Parvizi(Director)inXingjuan (Jane) Chao(President, CEO, Co-Founder & Director)inScott Blumberg(Executive Officer)inJoseph Taylor(Director)Raymond Woo(Executive Officer)David Stoffel(Executive Officer)

Co-investorsLongitude Capital Red Tree Venture ShangBay Capital LLC The Rise Fund

CG Oncologycgoncology.com in 𝕏NASDAQ: CGON

CG Oncology develops an investigational oncolytic immunotherapy for urologic cancer patients, specifically targeting BCG-unresponsive non-muscle invasive bladder cancer.

BiotechHealthtechMedical Devices

Arthur Kuan(Chairman and Chief Executive Officer)in

Co-investorsDecheng Capital Foresite Capital Longitude Capital Palm Drive Capital TCG Crossover ACORN BIOVENTURES +2 more

ClimbbioNASDAQ: CLYM

Climbbio is a clinical-stage biotechnology company developing monoclonal antibodies targeting B-cell pathways for immune-mediated diseases including primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus.

Andrew Levin(Director)Aoife Brennan(President and Chief Executive Officer, Director)

Collegium Pharmaceuticalcollegiumpharma.com in 𝕏NASDAQ: COLL

Collegium Pharmaceutical is a biopharmaceutical company developing a portfolio of medications to treat serious medical conditions.

BiotechCanton, US

Michael Heffernan(Executive Officer, Director)inPaul Brannelly(Executive Officer)in Vikram Karnani(President and Chief Executive Officer, and Director)in

BoardEran Nadav(Director)John Freund(Director)Patrick Heron(Director)in

Co-investorsAPERTURE Venture Partners EcoR1 Capital Frazier Life Sciences Longitude Capital Boston Millennia Partners

Connect Biopharmaconnectbiopharma.com inNASDAQ: CNTB

Connect Biopharma is a clinical-stage biopharmaceutical company developing antibody-based therapies targeting inflammatory diseases such as atopic dermatitis and asthma.

BiotechHealthtechSan Diego, US

Barry D. Quart(Chief Executive Officer and Director)in David Szekeres(President)inKimberly J. Manhard(Executive Vice President, Chief Development Officer)in

Co-investorsCo-Win Ventures

Crineticscrinetics.com in 𝕏NASDAQ: CRNX

Crinetics is a pharmaceutical company focused on discovering, developing, and commercializing therapies for endocrine diseases and endocrine-related conditions.

BiotechSan Diego, US

Richard Scott Struthers(Executive Officer, Director)Stephen F. Betz(Executive Officer)in Stephen Betz(Chief Scientific Officer)in R. Scott Struthers(President, Chief Executive Officer and Director)in Tobin Schilke(Chief Financial Officer)in Isabel Kalofonos(Chief Commercial Officer)in

Co-investors5AM Ventures Foresite Capital OrbiMed Vivo Capital

Cytek Biosciencescytekbio.com in 𝕏NASDAQ: CTKBOct 2020

Cytek Biosciences develops high-parametric analytical instruments and software that enable scientists at pharmaceutical companies, contract research organizations, and academic institutions to generate and analyze biological datasets.

BiotechDeep TechHardwareHealthtechMedical DevicesBellevue, US

Wenbin Jiang, Ph.D.(CEO and Chairman of the Board)Wenbin Jiang(Executive Officer, Director)inMing Yan, Ph.D.(Chief Technology Officer)Ming Yan(Executive Officer, Director)inJiecheng Zhang(Director)Allen Poirson(Director)

Co-investors3E Bioventures Capital F-Prime Capital Northern Light Venture Capital

Damora TherapeuticsNASDAQ: DMRANov 2025 · $284.9M

Damora Therapeutics is a preclinical-stage biotechnology company that discovers and develops therapeutic candidates, including DMR-001, DMR-002, and DMR-003, with the goal of advancing treatments through investigational drug applications and clinical trials.

BiotechCopenhagen, US

Garrett Winslow(Executive Officer)in Lori Firmani(Executive Officer)inHans T. Schambye(Executive Officer, Director)Jennifer Jarrett(President, Chief Executive Officer and Director)inBecker Hewes(Chief Medical Officer)Sherwin Sattarzadeh(Chief Operating Officer)

Co-investorsAccess Biotechnology BAM Elevate Bay City Capital Commodore Capital EIR Ventures Forbion +6 more

Designtxdesigntx.com inNASDAQ: DSGNJan 2021

Design Therapeutics is a biopharmaceutical company developing small molecule therapeutic candidates for serious genetic diseases through its GeneTAC (Gene Targeted Chimera) platform.

BiotechMedical DevicesSolana Beach, US

Pratik Shah, Ph.D.(Executive Officer, Director)Aseem Z. Ansari, Ph.D.(Director)Sean Jeffries, Ph.D.(Executive Officer)

BoardSimeon George, M.D.(Director)Stella Xu, Ph.D.(Director)Rodney Lappe, Ph.D.(Director)

Co-investorsAvoro Capital Advisors Quan Capital SR One Capital Management WestRiver Group Quan Venture

Diffusion Pharmaceuticalscervomed.com inNASDAQ: CRVO

CervoMed is a clinical-stage biopharmaceutical company developing neflamapimod, an investigational drug for neurodegenerative diseases such as nonfluent variant primary progressive aphasia and frontotemporal dementia.

BiotechHealthtechCharlottesville, US

John L. Gainer(Executive Officer, Director)inDavid G. Kalergis(Executive Officer, Director)inDavid R. Jones(Executive Officer)inBen L. Shealy(Executive Officer)John Moynahan(Executive Officer)Stephen Simes(Executive Officer, Director)

Dyne Therapeuticsdyne-tx.com in 𝕏NASDAQ: DYNAug 2020

Dyne Therapeutics develops targeted therapies for genetically driven neuromuscular diseases using its proprietary FORCE platform.

BiotechMedical DevicesWaltham, US

Romesh Subramanian, Ph.D.(Executive Officer)Richard Scalzo(Executive Officer)Joshua Brumm(Executive Officer, Director)Jonathan McNeill, M.D.(Executive Officer)inOxana Beskrovnaya, Ph.D.(Executive Officer)John G. Cox(Chief Executive Officer and President, Director)in

Co-investorsAtlas Venture MPM BioImpact Vida Ventures Forbion Hercules Capital, Inc.

Eliem TherapeuticsNASDAQ: CLYMMay 2021

Eliem Therapeutics is a clinical-stage biotechnology company developing monoclonal antibodies targeting immune-mediated diseases, with budoprutug, an anti-CD19 antibody designed to deplete B cells in conditions including primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL antibody for IgA nephropathy and related B-cell mediated diseases.

BiotechWilmington, US

Valerie Morisset(Executive Officer)inErin Lavelle(Executive Officer)inRobert Azelby(Executive Officer, Director)James Bucher(Executive Officer)Leone Patterson(Director)

BoardAdam Rosenberg(Director)

Co-investorsManta Ray Ventures Access Biotechnology ACORN BIOVENTURES

Enliven Therapeuticsenliventherapeutics.com inNASDAQ: ELVN

Enliven Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops small molecule therapeutics using a precision medicine approach, with a focus on oncology and hematology.

BiotechHealthtechBoulder, US

Sam Kintz(Co-founder and Head of Pipeline)inJoe Lyssikatos(Co-founder and Research Fellow)Anish Patel(Co-founder and Chief Operating Officer)Rick Fair(Chief Executive Officer and Member of the Board of Directors)inHelen Collins(Chief Medical Officer)in Ben Hohl(Chief Financial Officer and Head of Corporate Development)in

Co-investors5AM Ventures OrbiMed Pfizer Venture Investments Roche Venture Fund ARCH Venture Partners Bay City Capital +1 more

GH Researchghres.comNASDAQ: GHRS

A pharmaceutical company whose executive team emphasizes innovation and patient care.

BiotechDigital HealthMental Health

Co-investorsForesite Capital

Hemab Therapeuticshemab.com in 𝕏NASDAQ: COAG

Hemab develops targeted therapies for bleeding and clotting disorders such as Glanzmann thrombasthenia, Factor VII deficiency, Von Willebrand Disease, and heavy menstrual bleeding.

BiotechDigital HealthHealthtechMedical Devices

Co-investorsAccess Biotechnology Avoro Capital Advisors HealthCap Novo Holdings Sofinnova Partners Avoro Ventures

ImaraNASDAQ: ELVNMar 2019 · $63Macquired by Enliven Therapeutics · Feb 2023

Imara is a clinical-stage biopharmaceutical company developing small molecule therapeutics for unmet medical needs, currently advancing ELVN-001, a selective kinase inhibitor designed to treat chronic myeloid leukemia by targeting the BCR-ABL gene fusion.

BiotechCambridge, US

James G. McArthur(Executive Officer, Director)Christoph M. Adams(Executive Officer, Director)Richard Fair(President, Chief Executive Officer, Director)

BoardSara Nayeem(Director)Barbara Dalton(Director)David Mott(Director)

Co-investorsBay City Capital New Enterprise Associates (NEA)Alexandria Arix Bioscience Lundbeckfonden Ventures OrbiMed +2 more

Invivydinvivyd.com in 𝕏NASDAQ: IVVDSeries C · Apr 2021 · $340M

Invivyd develops monoclonal antibody medicines for the prevention and treatment of serious viral infectious diseases, starting with COVID-19 and other high-need indications.

BiotechHealthtech

Marc Elia(Founder)in

Co-investorsBain Capital Life Sciences Foresite Capital MRL Ventures Fund Premji Invest GV (Google Ventures)MITHRIL +3 more

KALA BIOkalarx.com inNASDAQ: KALA

A biopharmaceutical company developing an artificial intelligence infrastructure platform designed for on-premises deployment in biotechnology and pharmaceutical research environments, serving biotech firms and pharma companies seeking secure access to advanced AI capabilities while retaining control over proprietary biological data; the company is also evaluating strategic alternatives for its legacy mesenchymal stem cell secretome assets after discontinuing its lead rare eye disease therapeutic program.

BiotechArlington, US

Justin Hanes(Director)inKevin Pojasek(Executive Officer)inDarius Kharabi(Executive Officer)in Todd Bazemore(Executive Officer)in Mark Iwicki(Executive Officer, Director)inMary Reumuth(Executive Officer)in

Co-investorsLongitude Capital SR One Capital Management Ysios Capital Atlas Venture Lux Capital Third Rock Ventures

Monopar Therapeuticsmonopartx.comNASDAQ: MNPRDec 2024 · $40M

Monopar Therapeutics is a clinical-stage biotechnology company developing radiopharmaceuticals for oncology imaging and treatment of advanced solid tumors, along with ALXN1840, a late-stage investigational treatment for Wilson Disease, a rare genetic disorder.

BiotechHealthtechMedical DevicesLake Forest, US

Chandler D. Robinson(Executive Officer, Director, Promoter)inChristopher M. Starr(Executive Officer, Director)Andrew P. Mazar(Executive Officer, Director)

BoardMichael J. Brown(Director)

Co-investorsJanus Henderson Investors

Nateranatera.com in 𝕏NASDAQ: NTRA

Natera develops genetic tests and diagnostics using cell-free DNA technology to detect diseases including cancers, genetic disorders, and transplant-related conditions.

BiotechDigital HealthHealthtechMedical Devices

Matthew Rabinowitz(Co-founder & Executive Chairman)inJonathan Sheena(Founder)inSteven Chapman(Chief Executive Officer & President)

Co-investorsBain Capital Life Sciences Cheyenne Ventures Claremont Creek Ventures Foresite Capital Harmony Partners Lightspeed Venture Partners +2 more

Nkarta, Inc.nkartatx.com inNASDAQ: NKTXAug 2019

Nkarta is a biotech company developing allogeneic CAR NK cell therapies for autoimmune diseases, aiming to offer safer and more accessible alternatives to autologous CAR-T treatments.

BiotechHealthtechSouth San Francisco, US

Paul Hastings(Executive Officer, Director)inPaul H.inMatthew Plunkett(Executive Officer)inPaul J. Hastings(Chief Executive Officer)in

BoardMichael Dybbs(Director)Jill Carroll(Director)in

Co-investorsNew Enterprise Associates (NEA)Samsara BioCapital SR One Capital Management Amgen Ventures Logos Norwest Venture Partners +1 more

Olemaolema.com in 𝕏NASDAQ: OLMA

Olema is a clinical-stage biopharmaceutical company developing novel therapies for metastatic breast cancer and other endocrine-driven cancers, targeting nuclear receptors and mechanisms of acquired resistance.

BiotechHealthtechSan Francisco, US

Cyrus L. Harmon, Ph.D.(Director)Cyrus Harmon(Executive Officer, Director)in Cyrus L. Harmon(Director)inDavid C. Myles, Ph.D.(Executive Officer)Sean Bohen, M.D., Ph.D.(Executive Officer, Director)Naseem Zojwalla, M.D.(Executive Officer)in

Co-investorsAvoro Capital Advisors Bain Capital Life Sciences Foresite Capital Lightspeed Venture Partners Biotechnology Value Fund Logos +1 more

Parabilis Medicinesparabilismed.com inNASDAQ: PBLSJan 2026 · $305M

Helicons develops a peptide-based therapeutic platform designed to target intracellular proteins previously considered undruggable by combining the specificity of antibodies with the cell-penetrating properties of small molecules.

AI & Machine LearningBiotechDeep TechMedical Devices

Mathai Mammen(CEO, President and Chairman)in

Co-investorsARCH Venture Partners Catalio Capital Management, LP Foresite Capital Frazier Life Sciences General Catalyst Nextech Invest +7 more

PepGenpepgen.com in 𝕏NASDAQ: PEPG

PepGen is a clinical-stage biotech company developing oligonucleotide therapies for neuromuscular and neurological diseases using its Enhanced Delivery Oligonucleotide (EDO) platform to improve tissue penetration and uptake in muscle tissues.

AI & Machine LearningBiotechHealthtechMedical DevicesBoston, US

James McArthur(Executive Officer, Director)inNoel P. Donnelly(Chief Financial Officer)in Joseph D. Vittiglio(Chief Business & Legal Officer and Secretary)inKasra Kasraian(Chief Technical Officer)in

Board Ramin Farzaneh-Far(Director)inJoshua Resnick(Director)

Co-investorsOxford Science Enterprises

Precision BioSciencesprecisionbiosciences.com in 𝕏NASDAQ: DTIL

Precision BioSciences develops gene-editing medicines using its proprietary ARCUS genome editing platform, which employs sequence-specific nuclease enzymes to insert, remove, or repair DNA in living cells to treat hard-to-treat conditions including rare genetic diseases and hepatitis B (HBV).

BiotechDeep TechHealthtechDurham, US

DEREK JANTZ(Executive Officer, Director)inMATTHEW KANE(Executive Officer, Director)Jeff Smith(Co-founder)in Derek Jantz(Co-founder)inTODD MELBY(Executive Officer)in Michael Amoroso(President, Chief Executive Officer)in

Co-investorsage1 Agent Capital Aliment Capital Brace Pharma F-Prime Capital OCV Partners +4 more

Protagonist Therapeuticsprotagonist-inc.com in 𝕏NASDAQ: PTGXJul 2015

Protagonist is a company that emphasizes a diverse and inclusive corporate culture as central to its innovation, with stated goals of creating wins for its organization and for patients.

BiotechHealthtechMilpitas, US

Dinesh V. Patel, PhD(Executive Officer, Director)Dinesh Patel(President & Chief Executive Officer)

BoardAsish K. Xavier, Ph.D.(Director)Michael Panaccio, Ph.D.(Director)Armen Shanafelt, Ph.D.(Director)Paul F. Truex(Director)

Co-investorsAisling Capital Canaan Partners JJDC Johnson & Johnson Innovation – JJDC Lilly Ventures Starfish Ventures

Prothenaprothena.com in 𝕏NASDAQ: PRTAMar 2018

Prothena is a clinical-stage biotechnology company developing investigational therapies for neurodegenerative and rare peripheral amyloid diseases by targeting misfolded proteins.

BiotechDun Laoghaire, Co. Dublin, US

Tran B. Nguyen(Executive Officer)Arthur W. Homan(Executive Officer)Karin L. Walker(Executive Officer)inTara Nickerson, Ph.D.(Executive Officer)Wagner M. Zago, Ph.D.(Executive Officer)Carol D. Karp(Executive Officer)in

Co-investorsSofinnova Ventures Invesco Wellington Management

Pyxis OncologyNASDAQ: PYXS

Pyxis Oncology is a clinical-stage biotech company developing antibody-drug conjugates for solid tumors, with its lead candidate targeting a fibronectin variant found in tumor tissue but not healthy tissue.

HealthtechBoston, US

Thomas Civik(Interim Chief Executive Officer, Director)

Board David Steinberg(Executive Officer, Director)in Christoph Westphal(Director)Geeta Vemuri(Director)inJak Knowles(Director)John Flavin(Director)

Co-investorsAgent Capital Longwood Fund RTW Investments L.P.

Rani Therapeuticsranitherapeutics.com inNASDAQ: RANI

Rani Therapeutics develops oral drug delivery technology using robotic capsules to replace injectable biotherapeutics, addressing the challenge of delivering biologics through the gastrointestinal tract without needles.

BiotechDigital HealthHealthtechMedical DevicesSan Jose, US

Mir Hashim(Executive Officer, Director)in Talat Imran(Chief Executive Officer)in

BoardMir Imran(Founder)Andrew Farquharson(Director)in

Co-investorsInCube Ventures VHM

Rani Therapeutics HoldingsNASDAQ: RANIOct 2025

Rani Therapeutics is a clinical-stage biopharmaceutical company developing oral delivery technologies for biologics and drugs, primarily through its proprietary RaniPill capsule platform, which comes in two configurations (RaniPill GO for up to 3 mg microtablet doses and RaniPill HC for up to 200µL liquid doses).

BiotechSan Jose, US

Talat Imran(Executive Officer, Director)in Svai Sanford(Executive Officer)inMir Hashim(Executive Officer)in

BoardAbraham Bassan(Director)Vasudev Bailey, M.D.(Director)Mir Imran(Director)

Co-investorsInCube Ventures

Relmada Therapeuticsrelmada.comNASDAQ: RLMDMar 2026 · $160M

Relmada is a clinical-stage biopharmaceutical company developing therapies including NDV-01, a sustained-release intravesical formulation of gemcitabine and docetaxel for non-muscle invasive bladder cancer, and Sepranolone, a candidate targeting compulsive behaviors via GABAA receptor modulation.

BiotechHealthtechNew York, US

Sergio Traversa(Executive Officer, Director)Paul Kelly(Director)Maged Shenouda(Director)in Eliseo O. Salinas(President and Chief Scientific Officer)inDouglas Beck(Chief Financial Officer)Charles Ence(Chief Accounting and Compliance Officer)

Co-investorsBioAdvance BAM Elevate Braidwell Commodore Capital Janus Henderson Investors OrbiMed +2 more

Rxsightrxsight.com in 𝕏NASDAQ: RXST

RxSight develops the Light Adjustable Lens (LAL), an FDA-approved intraocular lens that surgeons can adjust after cataract surgery to fine-tune a patient's prescription once the eye has healed.

HealthtechMedical DevicesPasadena, US

Robert H. Grubbs(Director)Daniel M. Schwartz(Director)D. Verne Sharma(Executive Officer, Director)Richard Drinkward(Executive Officer)inRon Kurtz(President, Chief Executive Officer & Director)Mark Wilterding(Chief Financial Officer)in

Co-investorsFlying L Partners Foresite Capital H.I.G. Capital H.I.G. HealthBridge Partners Longitude Capital Visionary Ventures +2 more

Scribe Therapeuticsscribetx.com in 𝕏NASDAQ: SCTXMar 2021

Scribe is a molecular engineering company developing CRISPR-based genetic therapies to treat cardiometabolic disease and other conditions.

BiotechDeep TechHealthtechMedical DevicesBerkeley, US

Benjamin Oakes(Founder & CEO)inJennifer A. Doudna, PhD(Co-founder, Scientific Advisor)Benjamin L. Oakes, PhD(Co-founder, President and CEO)David F. Savage, PhD(Co-founder, Scientific Advisor)Brett Staahl, PhD(Co-founder, VP of External Innovation)

Board Vijay Pande(Director)in

Co-investorsAndreessen Horowitz OrbiMed Avoro Capital Advisors Menlo Ventures Avoro Ventures

Scynexisscynexis.com in 𝕏NASDAQ: SCYX

SCYNEXIS develops fungerp-based antifungal therapies, including SCY-247, for treating and preventing severe, progressive, and often fatal fungal diseases and antimicrobial-resistant infections.

BiotechDurham, US

Yves J. Ribeill(Executive Officer, Director)inCharles F. Osborne, Jr.(Executive Officer)Brian Schwab(Executive Officer)in David Angulo(Chief Executive Officer, President and Director)in

BoardLaurent Arthaud(Director)Mounia Chaoui(Director)

Co-investorsDecheng Capital Foresite Capital Deerfield Management Company

Seres Therapeuticsserestherapeutics.com in 𝕏NASDAQ: MCRB

Seres Therapeutics is a clinical-stage biotechnology company developing therapies composed of rationally selected live bacterial consortia to treat serious diseases through modulation of the human microbiome.

BiotechDigital HealthHealthtechMedical DevicesCambridge, US

Matthew Henn(President and Chief Scientific Officer)inJohn Aunins(Executive Officer)inEric D. Shaff(Executive Officer)in David Cook(Executive Officer)in Roger J. Pomerantz(Executive Officer, Director)inRichard N. Kender(Executive Chair and Interim Chief Executive Officer)

Co-investorsFlagship Pioneering Sofinnova Ventures Fidelity Investments

Solid Biosciencessolidbio.com in 𝕏NASDAQ: SLDB

Solid Biosciences is a precision genetic medicine company developing a pipeline of gene therapy candidates for rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy, Friedreich's ataxia, CPVT, and TNNT2-mediated dilated cardiomyopathy.

BiotechHealthtechCharlestown, US

Ilan Ganot(Co-Founder and Director)inStephen DiPalma(Executive Officer)Carl Morris(Executive Officer)inAlexander Cumbo(President, Chief Executive Officer and Director)Martin Freed(Director)inPaul Herizch(Executive Officer)

Co-investorsBain Capital Life Sciences Foresite Capital

Spyglass Pharmaspyglasspharma.com inNASDAQ: SGP

SpyGlass Pharma develops a sustained drug delivery platform for treating chronic ophthalmic diseases such as glaucoma, integrating drugs, procedures, and devices for long-term disease control and vision preservation.

BiotechHealthtechMedical DevicesAliso Viejo, US

Glenn Sussman(Co-founder)in Malik Y. Kahook(Co-founder)inPatrick Mooney(CEO)

BoardJake Merrill(Director)Geoff Pardo(Director)Bilal Khan(Director)

Co-investorsNew Enterprise Associates (NEA)Samsara BioCapital Sands Capital Ventures Vensana Capital

SutroVaxNASDAQ: PCVX

BiotechSouth San Francisco, US

Grant E. Pickering(Chief Executive Officer)Ashish Khanna(Executive Officer)Jeff Fairman(Executive Officer)

BoardTracy Saxton(Director)William Newell(Director)Kurt von Emster(Director)in

Co-investorsAbingworth CTI Life Sciences Fund L.P.Foresite Capital Frazier Life Sciences Janus Henderson Investors Longitude Capital +4 more

TYRA Biosciencestyra.bio inNASDAQ: TYRAFeb 2024

Tyra is developing oral dabogratinib, a small-molecule therapy being evaluated in clinical studies for skeletal dysplasia and urologic cancers.

BiotechHealthtechCarlsbad, US

Todd Harris, Ph.D.(Executive Officer, Director)Hiroomi Tada, M.D., Ph.D.(Executive Officer)Daniel Bensen(Executive Officer)inAlan Fuhrman(Executive Officer)inTodd Harris(President, Chief Executive Officer and Director)inBhavesh Ashar(Chief Operating Officer)in

Co-investorsAlta Partners BioBrit Nextech Invest Canaan Partners NEXTECH ONCOLOGY SCSP

Vaxcytevaxcyte.comNASDAQ: PCVX

Vaxcyte develops broad-spectrum vaccines to prevent bacterial infections, using a cell-free protein synthesis platform and synthetic chemistry techniques.

BiotechHealthtech

Grant Pickering(Founder)in Grant E. Pickering(Chief Executive Officer and Director)in

Co-investorsBioRock Ventures CTI Life Sciences Fund L.P.Foresite Capital Frazier Life Sciences Longitude Capital Janus Henderson Investors +2 more

Vor Biopharmavorbio.comNASDAQ: VORJun 2020

Vor Biopharma is a biopharmaceutical company.

BiotechCambridge, US

Nathan Jorgensen(Executive Officer)Amy Mendel(Executive Officer)Robert Ang(Executive Officer, Director)Jean-Paul Kress(President, Chief Executive Officer and Chairman of the Board)in

Board Kush Parmar(Director)inJoshua Resnick(Director)

Co-investors5AM Ventures OUP (Osage University Partners)PureTech Health

Xilio Therapeuticsxiliotx.com inNASDAQ: XLO

Xilio Therapeutics is a clinical-stage biotechnology company developing masked immuno-oncology therapies that use protein engineering to remain inactive until activated by tumor-specific proteases within the tumor microenvironment.

BiotechHealthtechWaltham, US

René Russo(Executive Officer, Director)inJoseph Farmer(Executive Officer)Timothy Clackson(Executive Officer)Christopher Frankenfield(Chief Financial and Operating Officer)in Katarina Luptakova(Chief Medical Officer)inPaul Clancy(Director)

Co-investorsBain Capital Life Sciences Bay City Capital F-Prime Capital M Ventures MRL Ventures Fund RiverVest Venture Partners +9 more

Bambusa Therapeuticsbambusatx.com inFeb 2025✓ verified

Bambusa Therapeutics develops bispecific antibodies for immunological and inflammatory (I&I) disorders, using antibody engineering to target multiple I&I indications.

BiotechHealthtechMedical DevicesAustin, US

Shanshan Xu(Founder & Chief Executive Officer)in Helmut Jeggle(Co-Founder)inThang Ho(Chief Development Officer)in Crystal MacKay(Chief Operating Officer)in

Board seat Derek DiRocco· per SEC Form D

Co-investorsINCE Capital Salvia Biotechnology Value Fund Janus Henderson Investors REDMILE

Outpace Biooutpacebio.com inJul 2024✓ verified

Outpace Bio develops engineered protein technologies and cell therapies to treat solid tumors, focusing on protein design and T cell engineering to improve cancer treatment efficacy and safety.

BiotechDeep TechMedical DevicesSeattle, US

Marc Lajoie(Co-founder & Chief Executive Officer)in Scott Boyken(Co-founder & Chief Innovation Officer)inStanley Riddell(Co-Founder and Scientific Advisor)Aaron Foster(Executive Officer)inCharity Scripture(Executive Officer)inEric Soller(Executive Officer)in

Board seat Jake Simson· per SEC Form D

Co-investorsArtis Ventures Abstract Ventures Atinum Investment Co. Ltd.Civilization Ventures Management, Llc Modi Ventures Playground Global +1 more

Stipple Biostipple.bio in 𝕏Mar 2026 · $100M✓ verified

Stipple Bio develops targeted oncology therapies that act on tumor-specific cell surface epitopes to expand druggable targets and improve therapeutic index for cancer patients.

BiotechHealthtechCambridge, US

Aaron Ring(Co-founder)in Aashish Manglik(Co-founder)inJeff Landau(Chief Executive Officer)in Roland Gendron(Chief Business Officer)in Michelle Zhang(Chief Scientific Officer)in

Board Vineeta Agarwala(Director)in

Board seat Derek DiRocco· per SEC Form D

Co-investorsAndreessen Horowitz Magnetic Ventures OMX Ventures Axial VC GV (Google Ventures)LoLa Capital Partners +1 more

Abcuroabcuro.comAug 2026✓ verified

Abcuro develops therapies that target highly cytotoxic T cells for autoimmune diseases, including its lead candidate ulviprubart for inclusion body myositis.

BiotechHealthtechNewton, US

Steven A. Greenberg(Chief Scientific Advisor & Co-Founder)Steven A. Greenberg, MD(Chief Scientific Advisor & Co-Founder)John Alexander Martin(Executive Officer, Director)Stefano Gulla(Executive Officer)Evan Thompson(Executive Officer)David de Graaf(Executive Officer, Director)

Co-investorsBain Capital Life Sciences New Enterprise Associates (NEA)Samsara BioCapital Sanofi Ventures Mass General Brigham Ventures REDMILE +9 more

Adcytherixadcytherix.com in✓ verified

Adcytherix is a clinical-stage biopharmaceutical company developing next-generation antibody-drug conjugates (ADCs) that use approved cancer drugs as payloads combined with optimized conjugation design to overcome resistance in precision oncology.

BiotechHealthtechMedical Devices

Jack Elands(Founder & CEO)in Xavier Preville(Co-founder, VP & Head of Research & Preclinical Development)in Jan H.M. Schellens(Chief Medical Officer)in Thierry Menguy(VP & Head of CMC Operations)in Jaime Arango(Chief Financial Officer)inPaul Jackson(Chief Operating Officer)in

Co-investorsaMoon Bpifrance Andera Partners Angelini Ventures Kurma Partners Pontifax Venture Capital +1 more

Alchemab Therapeuticsalchemab.com in 𝕏✓ verified

Alchemab operates a platform that identifies novel drug targets and therapeutics by analyzing patient antibody repertoires using deep B cell sequencing and computational analysis of samples from disease-resilient individuals.

AI & Machine LearningBiotechDeep TechHealthtech

Jane Osbourn(Chief Executive Officer)

Co-investorsSV Health Investors DCVC Bio Dementia Discovery Fund Lightstone Ventures Ono Venture Investment, Inc.British Business Bank +2 more

Alentisalentis.ch in✓ verified

Alentis is a biotech company developing therapies for chronic liver disease, fibrosis, and cancer based on the molecular biology of liver disease.

AI & Machine LearningBiotechHealthtechMedical DevicesBasel, CH

Thomas Baumert(Founder)inMark Pruzanski(Chief Executive Officer)in Luigi Manenti(Chief Medical Officer)inJon Freve(Chief Financial Officer)inBryan Yoon(General Counsel and Chief Administrative Officer)inAditya Venugopal(Chief Business Officer)in

Co-investorsAvego BioScience Capital BioMedPartners Frazier Life Sciences Jeito Capital Longitude Capital Novo Holdings +5 more

Atavistik Bioatavistikbio.com in✓ verified

Atavistik Bio develops selective allosteric therapeutics using a proprietary discovery platform designed to identify functional pockets across multiple protein classes, with an internal focus on rare hematology.

BiotechHealthtechMedical Devices

Bryan E. Stuart(Chief Executive Officer)inMarion Dorsch(President and Chief Scientific Officer)in

Co-investorsLux Capital The Column Group Nextech Invest

Avalanche Energyavalanchefusion.com in 𝕏Apr 2026 · $29M✓ verified

Avalanche Energy develops compact fusion technology to generate high-energy neutrons for materials testing, radioisotope production, and advanced nuclear battery systems serving defense, space, and commercial power applications.

Deep TechDefense TechEnergyRichland, US

Robin Langtry(Co-Founder, CEO)in Brian Riordan(Co-Founder, COO)in

Co-investorsCongruent Ventures Founders Fund Lowercarbon Capital Toyota Ventures Autodesk Foundation Azolla Ventures +4 more

Biabia.app in 𝕏Sep 2023✓ verified

Bia is a technology-driven electricity retailer in Colombia that lets businesses switch their energy provider and replace traditional meters with its proprietary BiaMonitor smart meter.

CleantechEnergyIoTBogota, CO

Sebastian Ruales(Founder)inGuillermo Plaza Roche(Director)Leonardo Velazquez Florez(Director)Juan Sebastian Ruales Duque(Director)Jaime E. Zunzunegui(Director)in

Board Nicolas Berman(Director)in

Co-investorsBBVA SPARK IDB Lab Kaszek Ventures Marathon Ventures Nazca Norte Ventures +4 more

Bright Peak Therapeuticsbrightpeaktx.com inJun 2021✓ verified

Bright Peak Therapeutics is a biotechnology company developing multi-functional PD-1 inhibitors for cancer immunotherapy, based on its EDC protein-engineering platform.

BiotechHealthtechSan Diego, US

Vijaya Pattabiraman(Co-founder & Chief Technology Officer)inJeffrey Bode(Scientific co-founder; Professor at ETH Zürich)inFredrik Wiklund(Chief Executive Officer)Christine Siu(Director)Michael Rosenzweig(Director)Bertolt Kreft(Executive Officer)

Co-investorsJohnson & Johnson Innovation – JJDC Versant Ventures Venrock Alexandria BlackRock Fidelity Investments +2 more

Capacity Biocapacitybio.com inDec 2022 · $35M✓ verified

Capacity Bio is a biotechnology company developing mitophagy modulators — small molecules, peptides, and nanoparticles that target mitochondrial biology to identify and clear dysfunctional mitochondria.

BiotechDeep TechLongevityPalo Alto, US

Amy Wang(PhD)in Kenneth Horne(Executive Officer, Director)in Dylan Morris(Director)in Cristina Ghenoiu(Director)in

Board Taro Inaba(Director)in

Co-investorsRemiges Ventures, Inc.Insight Partners AN Venture Partners RDiscovery

Cdr Lifecdr-life.com✓ verified

CDR-Life develops T cell engager immunotherapies for cancer and autoimmune diseases using its M-gager antibody platform, targeting both conventional tumor antigens and hard-to-treat targets.

BiotechHealthtechHorgen, CH

Rouven Bingel-Erlenmeyer(Founder)in Christian Leisner(Co-founder)inDominik Escher(Co-founder)

Co-investorsJeito Capital

Gracellbiogracellbio.com in✓ verified

Gracell Biotechnologies develops cell therapy manufacturing platforms and treatments, with a focus on CAR-T cell therapies for cancer and autoimmune diseases.

BiotechHealthtechMedical DevicesSuzhou, CN

William Wei Cao in

Co-investorsLAV Lilly Asia Ventures OrbiMed Exome Asset Management Janus Henderson Investors Pivotal Life Sciences +2 more

HYKU Bioscienceshykubiosciences.com inDec 2025✓ verified

Hyku Biosciences develops small molecule therapeutics with novel mechanisms of action designed to covalently bind non-cysteine amino acids and inactivate disease-driving proteins.

BiotechDeep TechMedical DevicesBurlington, US

KLEEM CHAUDHARY(Executive Officer, Director, Promoter)inKu-Lung (Ken) Hsu, PhD(Endowed Associate Professor of Chemistry)Kleem Chaudhary, PhD(President & CEO)

BoardJOHN GUSTOFSON(Director)LAURA BRASS(Director)in LAURA TADVALKAR(Director)in

Co-investorsDroia Ventures Eisai Innovation, Inc.Novartis Venture Fund

Indapta Therapeuticsindapta.comMay 2025 · $50M✓ verified

Indapta Therapeutics develops an off-the-shelf, allogeneic FcRγ-deficient natural killer (g-NK) cell therapy derived from healthy donors to treat cancer and autoimmune diseases.

BiotechHealthtechHouston, US

Guy DiPierro(Chief Operating Officer & Co-Founder)inSungjin Kim(Scientific Founder)John Sunwoo(Scientific Founder)Mark W. Frohlich(Chief Executive Officer)Stefanie Mandl-Cashman(Acting Chief Scientific Officer)

BoardLori Hu(Director)in

Co-investorsLeaps by Bayer Vertex Ventures HC

Kinaset Therapeuticskinasettherapeutics.com in 𝕏Jul 2020 · $103M✓ verified

Kinaset Therapeutics is a drug developer working on KN-002, a therapeutic candidate for treating severe asthma across patients regardless of the underlying cause of inflammation.

BiotechHealthtechMedfield, US

Roger Heerman(Chief Business/Operating Officer / Co-Founder)inFrazer Morgan(Chief Development Officer / Co-Founder)inRobert Clarke(Chief Executive Officer / Board Member / Co-Founder)Christopher O’Brien(Chief Medical Officer)

Board Jamil Beg(Director of the Issuer)inTom King(Director of the Issuer)

Co-investors5AM Ventures Atlas Venture EQT Life Sciences Sixty Degree Capital Vivo Capital Gimv +3 more

Medical Micro Instrumentsmmimicro.com in 𝕏Feb 2024✓ verified

MMI develops miniaturized robotic surgical instruments and platforms to enable surgeons to perform complex microsurgery and supermicrosurgery on delicate anatomical structures with greater precision.

HealthtechMedical DevicesRoboticsJacksonville, US

Mark Toland(Executive Officer, Director)inAndrew Cleeland(Director)Justin Lynch(Director)inTheresa Jean Cameron(Director)Caleb Moore(Executive Officer)Augusto Vianna Castello(Director)

Co-investorsAndera Partners BioStar Capital Deerfield Management Company Fidelity Investments Corewell Health Ventures Fountain Healthcare Partners

Pahrtxpahrtx.com✓ verified

PAhR Therapeutics is a clinical-stage biotech company developing novel mechanisms to treat pulmonary arterial hypertension (PAH).

BiotechHealthtech

Co-investorsAN Venture Partners UTEC

Pluton Biosciencesplutonbio.com in✓ verified

Pluton is developing a sun-powered, soil-surface biological nutrient system that uses photosynthetic microbial consortia to fix atmospheric nitrogen, improve phosphorus availability, and add carbon to soil for crop growers.

AgTechBiotechClimate TechSt. Louis, US

Barry Goldman(Co-founder)inElizabeth Gallegos(Chief Executive Officer)in Jerry Steiner(Executive Chair)in Charlie Walch(Executive Officer, Director)inGlendon Schuster(Director)

Co-investorsFirst In Ventures Illumina Ventures Radicle Growth Better Ventures Fall Line Capital Grantham Foundation +4 more

Sydnexissydnexis.com in✓ verified

Sydnexis is a privately held biopharmaceutical company developing SYD-101, a proprietary low-dose atropine formulation in Phase 3 clinical trials to slow the progression of pediatric progressive myopia.

BiotechDigital HealthDel Mar, US

Patrick Johnson(Executive Officer, Promoter)inMary Jaqueline Johnson(Executive Officer)Mary Jacqueline Johnson(Executive Officer)Kevin Johnson(Director)Greg Ostrow(Executive Officer, Director)Kenneth Widder(Executive Officer, Director)

Co-investorsLongitude Capital Visionary Ventures

Synolo Therapeuticssynolotx.com in✓ verified

Synolo Therapeutics develops conditionally-active immunotherapies for treating cancer, using a proprietary discovery platform to build a pipeline of oncology drug candidates.

BiotechHealthtech

Triana Biotrianabio.com in 𝕏✓ verified

TRIANA Biomedicines is a venture-backed biopharmaceutical company developing small-molecule "molecular glue" therapeutics that induce protein:protein interactions to degrade or alter disease-causing target proteins, with an initial focus on targeted protein degradation for cancer.

BiotechDeep TechHealthtechLexington, US

Patrick Trojer(President & Chief Executive Officer)in

Co-investorsAscenta Capital Atlas Venture Lightspeed Venture Partners Bessemer Venture Partners Pfizer Ventures Pfizer Venture Investments +2 more

visit www.enarabio.comenarabio.com in 𝕏✓ verified

Enara Bio discovers and validates Dark Antigens from non-coding genomic regions to identify novel cancer targets, and develops first-in-class bispecific T-cell engagers against these targets through its EnTiCE platform.

BiotechDeep TechMedical Devices

George Kassiotis(Co-founder)Drew Pardoll(Co-founder)Houman Ashrafian(Co-founder)in

Co-investorsPfizer Ventures Samsara BioCapital SV Health Investors Pfizer Venture Investments M Ventures

Vivace Therapeuticsvivacetherapeutics.comJul 2026✓ verified

Vivace Therapeutics is an oncology-focused drug discovery and development company creating small-molecule inhibitors targeting the Hippo-YAP pathway to treat cancers including mesothelioma, meningioma, and various other tumor types.

BiotechHealthtechMedical DevicesSan Mateo, US

Shuang Qiao(Executive Officer, Director)Sheng Ding(Executive Officer)

BoardEdward Hu(Director)Jun Wu(Director)Jake Simson(Director)in Tim Shannon(Director)in

Co-investorsCanaan Partners Cenova Capital Mission Biocapital

Voro Metalsvorometals.com✓ verified

Voro Metals operates a patent-pending pyrometallurgical process that removes residual copper and other contaminant metals from recycled scrap steel, upgrading low-grade feedstock into higher-value material.

Circular EconomyCleantechNew Materials

Acrivon Therapeuticsacrivon.comNov 2021

Acrivon is a clinical-stage oncology company developing precision medicine therapeutics for cancer treatment, using its proprietary AP3 proteomics platform to create companion diagnostics that match patients to drugs based on tumor-driving mechanisms.

AI & Machine LearningBiotechHealthtechMedical DevicesBoston, US

Peter Blume-Jensen(Executive Officer, Director)Kristina Masson(Executive Officer, Director)erick gamelin in Eric Devroe(Executive Officer)in

BoardMarcin Czernik(Director)Sharon Shacham(Director)

Board seat Derek DiRocco· per SEC Form D

Co-investorsNew Enterprise Associates (NEA)Pureos Bioventures

Ars Pharmaars-pharma.com in 𝕏Aug 2021 · $55M

ARS Pharmaceuticals is a biopharmaceutical company developing treatments for severe allergic reactions, with a focus on patient-friendly, easy-to-use intranasal therapies.

BiotechHealthtechMedical DevicesSan Diego, US

Richard Lowenthal(Executive Officer, Director)inPratik Shah(Director)

BoardJonathan Leff(Director)

Board seat Peter Kolchinsky· per SEC Form D

Co-investorsNextech Invest OrbiMed SR One Capital Management

Artivabioartivabio.com in 𝕏Jun 2020

Artiva Bio is a clinical-stage biotechnology company developing NK cell-based therapies for autoimmune diseases, designed to be manufactured at scale and delivered in community settings.

BiotechHealthtechMedical DevicesSan Diego, US

Jennifer Bush(Executive Officer)inThomas J. Farrell(Executive Officer)Fred Aslan(Executive Officer, Director)inJason Litten(Executive Officer)inEsther van den Boom(Executive Officer)Peter Flynn(Executive Officer)in

Board seat Laura Stoppel· per SEC Form D

Co-investors5AM Ventures EcoR1 Capital venBio Partners venBio Global Strategic

Day One Biopharmaceuticalsdayonebio.com in 𝕏Feb 2021SEC filingmedium confidence

Day One is a biopharmaceutical company that develops first- or best-in-class targeted medicines for children and adults with life-threatening diseases, with a focus on cancers such as pediatric brain tumors.

BiotechHealthtechSouth San Francisco, US

Jeremy Bender(Executive Officer, Director)

Board Michael Gladstone(Director)inJulie Papanek Grant(Director)in John Josey(Director)inDaniel Becker(Director)

Board seat Derek DiRocco· per SEC Form D · $130M raise · filed Feb 2021

Co-investorsAccess Biotechnology Atlas Venture Canaan Partners Access Industries The Column Group

Evommuneevommune.com inOct 2024

Evommune develops therapies targeting the underlying sources of chronic inflammatory diseases, aiming to provide underserved patient populations with more than symptomatic relief.

BiotechHealthtechPalo Alto, US

Luis Pena(Executive Officer, Director)inJanice Drew(Executive Officer)David Cohen(Director)Gregory Moss(Executive Officer)Eugene Bauer(Executive Officer, Director)Francois Beaubien(Director)

Board seat Derek DiRocco· per SEC Form D

Co-investorsAndera Partners Avego BioScience Capital B Capital Group B4 Capital Beiersdorf Innovation Fund FemHealth Ventures +3 more

G1 Therapeuticsg1therapeutics.comApr 2016

G1 Therapeutics develops cancer therapies focused on improving patient outcomes and quality of life for people with cancer.

BiotechResearch Triangle Park, US

Jay Strum(Executive Officer)Norman Sharpless(Director)Mark A. Velleca(Executive Officer, Director)inThomas K Laundon(Executive Officer)Timothy Sullivan(Director)Gregory Mossinghoff(Executive Officer)

Board seat Peter Kolchinsky· per SEC Form D

Co-investorsLumira Ventures Mountain Group Capital Solasta Ventures Hatteras Venture Partners

Icosavaxicosavax.comMar 2021

BiotechSeattle, US

Charles Richardson(Senior Vice President, Technical Operations)Adam K. Simpson(President and Chief Executive Officer)Niranjan Kanesa-thasan(Chief Medical Officer)Douglas A. Holtzman(Chief Scientific Officer and Secretary)Cassia Cearley(Treasurer, Chief Business Officer)

Board seat Peter Kolchinsky· per SEC Form D

Co-investorsSanofi Ventures Qiming Healthcare

Rivus Pharmaceuticals, Inc.rivuspharma.com in 𝕏Jan 2025SEC filingmedium confidence

Rivus Pharmaceuticals develops mitochondrial-targeted therapies to treat cardiometabolic diseases.

BiotechDigital HealthHealthtechMedical DevicesCharlottesville, US

Francisco Portell(Co-founder & Vice President, Pharmaceutical Development)Allen Cunningham(Co-founder & Chief Operating Officer)inNancy Hargreaves(Executive Officer)Jayson Dallas(Executive Officer, Director)inShaharyar Khan(Co-founder & Chief Scientific Officer)in

Board Francesco De Rubertis(Director)in

Board seat Derek DiRocco· per SEC Form D · $57M raise · filed Jan 2025

Co-investorsMedicxi Bain Capital Life Sciences Longitude Capital

Septernasepterna.com inJun 2023

Septerna is a biotechnology company that uses its proprietary Native Complex Platform to discover and develop oral small molecule therapies targeting GPCRs for endocrinology, immunology and inflammation, and metabolic diseases.

AI & Machine LearningBiotechDeep TechSouth San Francisco, US

Robert Lefkowitz(Founder)Arthur Christopoulos(Founder)Patrick Sexton(Founder)Ran Xiao(Executive Officer)inElizabeth Bhatt(Executive Officer)Samira Shaikhly(Executive Officer)in

Board seat Jake Simson· per SEC Form D

Co-investorsCatalio Capital Management, LP Samsara BioCapital Vertex Ventures HC Third Rock Ventures

Werewolf Therapeuticswerewolftx.com inDec 2020

Werewolf Therapeutics is a biotechnology company developing immunotherapy treatments for cancer.

BiotechHealthtechMedical DevicesWatertown, US

Daniel J. Hicklin(Founder, President, Chief Executive Officer, and Board member)Luke Evnin(Co-founder, Board member (Chairman))inDaniel Hicklin(Executive Officer, Director)David Cordo(Executive Officer)Alon Lazarus(Director)

Board Christoph Westphal(Director)

Board seat Derek DiRocco· per SEC Form D

Co-investorsDC Investment Partners K2 HealthVentures Longwood Fund MPM BioImpact Taiho Ventures, LLC

Adcendo ApSadcendo.com

Adcendo develops antibody-drug conjugates (ADCs) targeting cancers with high unmet medical need.

BiotechMedical Devices

Co-investorsVida Ventures HealthCap Jeito Capital Novo Holdings OrbiMed Pontifax Venture Capital +2 more

Aiolos Bioaiolosbio.com in 𝕏

Aiolos Bio is a biopharma company that discovers, develops, and delivers medicines and vaccines across respiratory, immunology, inflammation, oncology, HIV, and infectious diseases.

BiotechHealthtech

Co-investorsBain Capital Life Sciences Sofinnova Ventures

Ajax Therapeutics Inc.ajaxtherapeutics.comAcquired

Ajax Therapeutics is a biotech company developing Type II JAK2 inhibitors for the treatment of myeloproliferative neoplasms (MPNs), including myelofibrosis, using computational chemistry and structural biology in its drug discovery.

AI & Machine LearningBiotechHealthtechNew York, US

Martin Vogelbaum(CEO, co-founder)inRoss Levine(Director)Ramy Farid(Director)

BoardScott Platshon(Director)

Co-investorsInning One Ventures EcoR1 Capital Vivo Capital

Akouosakouos.com in

Akouos is a precision genetic medicine company developing therapies for the inner ear to restore, improve, and preserve hearing.

BiotechHealthtechBrookline, US

Emmanuel Simons(Executive Officer, Director)william sewell(Founder)in

BoardEd Mathers(Director)in Kush Parmar(Director)in

Co-investors5AM Ventures EcoR1 Capital New Enterprise Associates (NEA)Sofinnova Ventures Cowen Healthcare Investments Fidelity Investments +1 more

Alpha-9 Oncologya9oncology.com inOct 2024

Alpha-9 Oncology develops radiopharmaceuticals for cancer treatment, with a portfolio of molecules in clinical and preclinical development.

BiotechDigital HealthMedical DevicesVancouver, CA

François Bénard(MD)Kuo-Shyan Lin(PhD)David Perrin(PhD)

Co-investorsAndreessen Horowitz Ascenta Capital Delos Capital General Catalyst Lightspeed Venture Partners Longitude Capital +9 more

AltruBioaltrubio.comMay 2024 · $225M

AltruBio develops antibody-based therapeutics for immunological and inflammatory diseases, with clinical-stage candidates (ALTB-268 and ALTB-168) targeting conditions such as ulcerative colitis, psoriatic arthritis, psoriasis, and acute graft versus host disease.

BiotechHealthtech

Co-investorsaMoon Delos Capital Biotechnology Value Fund Soleus Capital

AM Batteriesam-batteries.com

AM Batteries develops Powder to Electrode dry coating technology for lithium-ion electrode manufacturing, reducing solvent use and energy consumption compared to traditional slurry methods.

Advanced ManufacturingCleantechEnergyMassachusetts, US

Yan Wang(Director)in

Board Anil Achyuta(Director)in Jimmy Kan(Director)in Lisa Coca(Director)inLie Shi(Director)in

Co-investorsAnzu Partners Creative Ventures Foothill Ventures Asymmetric Capital Partners Breakthrough Energy Ventures TDK Ventures +1 more

Ambagon Therapeuticsambagontx.com in 𝕏Jan 2025

Ambagon develops small molecule stabilizers of 14-3-3 protein complexes to modulate disease-related protein interactions, targeting therapeutic areas including cancer, metabolic disorders, neurodegenerative and infectious diseases.

BiotechDeep TechMedical DevicesEindhoven, US

Christian Ottmann(Executive Officer)inJosh Seidenfeld(Executive Officer)Michelle Arkin(Director)Nancy Pryer(Executive Officer)Margarita Chavez(Director)Bryan Miller(Executive Officer)

Co-investorsDroia Ventures Mission Biocapital MRL Ventures Fund Nextech Invest Inkef

Angitia Bioangitiabio.com

Angitia Bio is a biopharmaceutical company developing therapies for musculoskeletal and related diseases.

Biotech

Co-investorsAscenta Capital Frazier Life Sciences OrbiMed Frazier

Ansa Biotechnologiesansabio.com in 𝕏

Ansa provides an enzymatic DNA synthesis platform that directly synthesizes complex sequences up to 900 bp and delivers constructs up to 50 kb without assembly-based methods.

BiotechDeep TechHealthtechEmeryville, US

Dan Lin-Arlow(Founder)in Sebastian Palluk(Founder)inDaniel Lin-Arlow(Executive Officer, Director)inDaniel Hillel Lin-Arlow(Executive Officer, Director)Jason T. Gammack(Executive Officer, Director)in

BoardYanniv Dorone(Director)

Co-investorsCarbon Silicon Cerberus Ventures Dauntless Ventures Fifty Years Metaplanet Y Combinator +3 more

Antios Therapeuticsantiostherapeutics.com in 𝕏Nov 2021 · $75M

Antios Therapeutics develops antiviral therapies for hepatitis B virus (HBV) and other viral diseases, including its Active Site Polymerase Inhibitor Nucleotide (ASPIN) ATI-2173 and a capsid assembly modulator program.

BiotechHealthtechMendham, US

Gregory Mayes(Executive Officer, Director)Douglas Mayers(Executive Officer)in Tamra Adams(Executive Officer)inAbel De La Rosa(Director)

BoardIyona Rajkomar(Director)inBenjamin Rovinski(Director)

Co-investorsAisling Capital Altium Capital Avego BioScience Capital Pontifax Venture Capital Amzak Health Delos Capital +8 more

Apeiron Labsapeironlabs.com

Apeiron Labs develops autonomous underwater vehicles and ocean technology for marine applications.

Climate TechDeep TechIoTRoboticsCambridge, US

Ravi Pappu(CEO / Board Member)in

Board Sanjeev Krishnan(Director)Jonathan Rosen(Director)David Douglas(Director)Kyle Teamey(Director)inMark Abbott(Director)

Co-investorsBay Bridge Ventures Climate Coalition S2G Investments TFX Capital Breakthrough Energy Ventures

Artios Pharmaartios.com in 𝕏Nov 2025 · $115M

Artios develops DNA damage response (DDR)-based medicines targeting patients with high unmet need cancers.

BiotechHealthtechMedical Devices

Co-investorsAndera Partners M Ventures Novartis Venture Fund Pfizer Venture Investments Sofinnova Partners SV Health Investors +2 more

Ascendis Pharmaascendispharma.com in 𝕏Nov 2014

Ascendis Pharma is a biopharmaceutical company developing therapies for hormone-related disorders and rare diseases.

BiotechHealthtechMedical DevicesDenmark, DK

Jan Møller Mikkelsen(Founder, President and Chief Executive Officer)inGrethe Rasmussen(Executive Officer)inHarald Rau(Executive Officer)Martin Olin(Director)Lotte S?nderbjerg(Executive Officer)Martin Auster(Executive Officer)in

Co-investorsVivo Capital Aisling Capital Avoro Capital Advisors Foresite Capital Sofinnova Ventures

Asher Bioasherbio.com in 𝕏Apr 2024 · $55M

Asher Bio develops selective immunotherapy drugs that target specific immune cell types to promote beneficial effects while minimizing toxicity.

BiotechHealthtechMedical DevicesSan Francisco, US

Ivana Djuretic(Founder)inAndy Yeung(Founder)in

Co-investorsEmles Venture Partners GoAhead Ventures Mission Bay Capital Mission Biocapital Y Combinator Alexandria +4 more

Audentes Therapeuticsastellasgenetherapies.com in

BiotechSan Francisco, US

Matthew Patterson(Executive Officer, Director)in

Board Jonathan Silverstein(Director)inSteve Squinto(Director)in Kush Parmar(Director)inJonathan Leff(Director)Thomas Woiwode(Director)

Co-investorsAsset Management Company venBio Partners 5AM Ventures Deerfield Management Company OrbiMed Venrock

Avalancheuseavalanche.comApr 2026 · $29MDefunct

Avalanche provides software development tools that startups can integrate to build and operate referral programs within their products.

Enterprise SoftwareMarketing TechSan Francisco, US

Elezhan (Ijan) Zhakiya(Founder)in

Co-investorsLowercarbon Capital Y Combinator 8090 Industries Congruent Ventures Founders Fund Toyota Ventures

Avalancheavax.network in 𝕏Apr 2026 · $29M

The Avalanche Foundation is a non-profit organization that supports innovation and growth in the Avalanche ecosystem through grants, programs, and strategic support for developers, entrepreneurs, and communities building on the Avalanche blockchain platform.

Crypto & Web3Data & InfrastructureDeveloper ToolsEnterprise SoftwareFintech

Emin Gun Sirer(Founder)in

Co-investorsa16z crypto Aegis Ventues Andreessen Horowitz Andromeda Capital BaseTwo Big Brain Holdings +25 more

Avalancheavalabs.org in 𝕏Feb 2026 · $29M

Ava Labs is a company building blockchain infrastructure and tools for creating and using finance applications.

Crypto & Web3Data & InfrastructureDeep TechFintechNew York City, US

Emin Gün Sirer(Founder & CEO)in

Co-investorsAnimoca Brands Abstract Ventures Ceras Ventures Continue Capital Lvna Capital 8090 Industries +5 more

Avilar Therapeuticsavilar-tx.com in 𝕏

Avilar develops ATACs (ASGPR Targeting Chimeras), a class of protein degraders designed to target extracellular and membrane-bound proteins by harnessing the endolysosome's natural degradation process.

BiotechWaltham, US

THERESA CAMERON(Director)MARTIN FREED(Director)inSTEPHANIE TOZZO(Executive Officer)PHIL GRAHAM(Executive Officer)MILIND DESHPANDE(Director)DAVID NEAFUS(Executive Officer)

Co-investorsAstellas Venture Management LLC Medical Excellence Capital Sanofi Ventures OpenSky Ventures

Azalea Therapeuticsazaleatx.com inNov 2025

Azalea Therapeutics develops precision genome editing therapies that engineer T cells directly inside the patient's body to create cancer immunotherapies, using proprietary delivery vehicles to target and modify specific genetic loci without ex vivo cell manipulation.

AI & Machine LearningBiotechMedical DevicesSan Francisco, US

Jennifer Doudna(Co-founder, Nobel Laureate in Chemistry and Li Ka Shing Chancellor's Chair in Biomedical and Health Sciences, UC Berkeley)Rodolphe Barrangou(Co-founder, Associate Professor of Medicine, UCSF)Krishnendu Roy(Co-founder, Professor of Bioengineering, Stanford University)Connor Tsuchida(Scientific Cofounder)in

Co-investorsThird Rock Ventures Sozo Ventures Yosemite

Bluebird Biobluebirdbio.com in 𝕏Sep 2021Acquired

Genetix Biotherapeutics (formerly bluebird bio) develops gene therapies for patients with rare genetic diseases including sickle cell disease, beta-thalassemia, and cerebral adrenoleukodystrophy.

BiotechLongevityMedical DevicesCambridge, US

David Meek(Chief Executive Officer)inBrian Riley(President & Chief Technical Officer)in Joanne Lager(Chief Medical Officer)in Wendy DiCicco(Chief Financial Officer)in Adrian Chaisson(Chief of Staff)inJason Cole(Executive Officer)

Co-investorsARCH Venture Partners Easton Capital Sanofi Ventures

Bluejay Therapeutics inMay 2024 · $182Macquired by Mirum Pharmaceuticals · Dec 2025 · $620M

Healthcare company acquired by Mirum Pharmaceuticals, a former RiverVest portfolio company.

San Mateo, US

Keting Chu(Executive Officer, Director)inDajun Yang(Director)Nancy Hong(Director)inAlon Lazarus(Director)William J. Rutter(Director)Ting Jia(Director)

Co-investorsFrazier Life Sciences RiverVest Venture Partners Frazier Healthcare Partners HBM Healthcare Investments Novo Holdings T. Rowe Price +1 more

Blueprint Medicinesblueprintmedicines.com in 𝕏

Blueprint Medicines is a biopharmaceutical company that discovers and develops targeted medicines for patients with diseases such as gastrointestinal stromal tumor and other conditions driven by genetic changes.

BiotechHealthtechCambridge, US

Nick Lydon(Director)Christoph S. Lengauer(Executive Officer)inChristine Bellon(Executive Officer)inKyle Kuvalanka(Executive Officer)in

BoardAlexis Borisy(Executive Officer, Director)Daniel Lynch(Director)

Co-investorsF-Prime Capital Foresite Capital Nextech Invest

Capstan Therapeuticscapstantx.com in 𝕏

AbbVie is a biopharmaceutical company that discovers and delivers medicines for immune-mediated diseases and other therapeutic areas globally.

BiotechHealthtechMedical DevicesSan Diego, US

Adrian Bot(Executive Officer)Laura Shawver(Executive Officer, Director)in Ramin Farzaneh-Far(Executive Officer)inJustin Thacker(Executive Officer)Karen Smith(Director)Fabio Pucci(Director)

Co-investorsPfizer Venture Investments Sofinnova Ventures Vida Ventures

Celea Therapeuticsceleatx.com inJul 2026 · $180M

Celea develops deupirfenidone, a pulmonary therapeutic targeting idiopathic pulmonary fibrosis in partnership with physicians and patient advocacy organizations.

BiotechHealthtechMedical Devices

Co-investorsPureTech Health Leaps by Bayer

CellCentriccellcentric.com in 𝕏

CellCentric develops inobrodib, a small-molecule oral p300/CBP inhibitor intended to treat multiple myeloma and other cancers.

BiotechHealthtechMedical Devices

Azim Surani(Co-founder)

Co-investorsAvego BioScience Capital Future Planet Capital BrightEdge Forbion Venrock

Cidara Therapeuticscidara.com in 𝕏

Pharmaceutical company developing medicines and vaccines for patient health and treatment.

BiotechHealthtechSan Diego, US

Jeffrey Stein(Executive Officer, Director)Kevin Judice(Director)inKevin Forrest(Executive Officer)Dirk Thye(Executive Officer)inKen Bartizal(Executive Officer)in Paul Daruwala(Executive Officer)in

Co-investors5AM Ventures Aisling Capital Bain Capital Life Sciences Frazier Life Sciences Vivo Capital Canaan Partners +1 more

Civitas Therapeuticscivitastherapeutics.comAug 2014

BiotechChelsea, US

RICHARD BATYCKY(Executive Officer)GLENN BATCHELDER(Director)BRYAN STUART(Executive Officer)in MARK IWICKI(Executive Officer, Director)in MARTIN FREED(Executive Officer)in

Board ROB HOPFNER(Director)in

Co-investorsCanaan Partners Sofinnova Ventures Bay City Capital Longitude Capital OrbiMed

Claris Bioclarisbio.com in

Claris Bio develops biologic therapies for sight-threatening eye diseases, with a current focus on bringing CSB-001, a novel treatment for patients with limbal stem cell deficiency, through clinical development and to market.

BiotechHealthtechMedical DevicesJersey City, US

Clarke Atwell(Co-Founder and Chief Operating Officer)inHenry Rath(Executive Officer)Susan Orr(Executive Officer)inStephen Brady(Executive Officer, Director)Michael Dybbs(Director)Matt Hobson(Director)

Co-investorsCatalio Capital Management, LP Sofinnova Ventures Catalio Capital Management Novo Holdings Samsara BioCapital

Climbclimb.frMay 2026 · $110M

Climb is a French wealth management service that combines advisors with technology to grow clients' assets through an open-architecture selection of investment products (life insurance, retirement PER, real estate, private equity, tax-reduction schemes, crypto).

FintechSaaS

Aldric Emié(CEO)in

Co-investorsKima Ventures Ally Bridge Group REDMILE

Commonscommons.co

Commons produces CBD gummies marketed for relaxation and wellness purposes, sold direct-to-consumer through their online store.

ConsumerDirect to ConsumerWellness & Fitness

BoardTahira

Co-investorsEmles Venture Partners Courtside Ventures Floating Point SteelSky Ventures Time BioVentures

Commons Cliniccommonsclinic.com

Commons Clinic is an orthopedic care provider offering treatment for spine, joint, and sports medicine conditions, along with preventive health services such as full-body MRI and biomarker labs.

Digital HealthHealthtechWellness & FitnessAustin, US

Brad Hively(Director)in Nick Aubin(Founder)inPaulo Marques Da Costa(Executive Officer, Director)Prithviraj Singha Roy(Director)in

Board John Loser(Director)in David Berry(Director)

Co-investorsCourtside Ventures Floating Point North South Ventures SteelSky Ventures Time BioVentures Averin Capital +1 more

Contralinecontraline.com inMay 2026

Contraline develops new contraceptive and reproductive health technologies, with a focus on male contraception.

BiotechDigital HealthMedical DevicesCharlottesville, US

Kevin Eisenfrats(Co-Founder and CEO)inJohn Herr(Co-Founder)

BoardIris Van Alderwerelt van Rosenburgh(Director)Gurdane Bhutani(Director)inMartin J Emerson(Director)Tom Thorpe(Director)

Partner Laura Stoppel· quoted

Co-investorsBiotechnology Value Fund MBX Capital Allied Venture Partners Amboy Street Ventures Aurum Venture Partners Beni Venture Capital +15 more

Convergentconvergent.org inMay 2023 · $90M

Convergent provides an AI simulation platform for enterprise training and skill development.

AI & Machine LearningEnterprise SoftwareHR TechSaaSLondon, GB

Co-investorsTechstars Andreessen Horowitz OrbiMed

Curevo Vaccinecurevovaccine.com inMar 2025 · $110M

Curevo Vaccine is a biotech company developing next-generation non-mRNA vaccines, with a focus on infectious diseases.

BiotechHealthtech

George Simeon(CEO)inGregory S. Curhan(CFO)Guy De La Rosa(CMO)in

Co-investorsAdjuvant Capital OrbiMed Sanofi Ventures HBM Healthcare Investments Janus Henderson Investors Medicxi

Cyteir Therapeuticscyteir.com in 𝕏Feb 2021 · $80M

Cyteir is a clinical-stage oncology company developing CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters.

BiotechHealthtechCambridge, US

Kevin Mills(Executive Officer, Director)inRonald Goldstein(Executive Officer)in Donald Corcoran(Executive Officer, Director)in Markus Renschler(Director)in

BoardTimothy Romberger(Director)Barry Mills(Director)

Co-investorsDroia Ventures Lightstone Ventures OUP (Osage University Partners)Ally Bridge Group De Novo Ventures Janus Henderson Investors +3 more

DealFormadealforma.com in 𝕏May 2024

DealForma provides a data platform and analyst support for biopharma business development teams to research partnerships, deals, funding trends, and therapeutic areas.

BiotechData & InfrastructureHealthtechSaaS

Chris

Co-investorsTinySeed Alger REDMILE RTW Investments L.P.Sofinnova Ventures

Delixdelixtherapeutics.com inSep 2021 · $70M

Delix Therapeutics develops third-generation, non-hallucinogenic neuroplastogens for people with neurological conditions, using a discovery platform to identify novel compounds.

BiotechDigital HealthMedical Devices

Co-investorsArtis Ventures Casa Verde Capital Noetic OMX Ventures PsyMed Ventures Vertical Venture Partners +6 more

Dicerna Pharmaceuticalsdicerna.com 𝕏

A pharmaceutical company developing treatments for serious chronic diseases with a focus on long-term health solutions and improving medicine access and affordability globally.

BiotechDigital HealthHealthtech

Co-investorsAccess Biotechnology Bain Capital Life Sciences Oxford Bioscience Partners

Dignify Therapeuticsdignifytherapeutics.com in

Dignify Therapeutics develops "on demand" drugs that trigger emptying of the bladder and/or bowel when a person chooses, aimed at restoring control of bowel and bladder function.

BiotechDigital HealthMedical DevicesResearch Triangle Park, US

Edward C Burgard(Executive Officer, Director, Promoter)Karl Thor(Executive Officer, Director, Promoter)in Benny Ward(Executive Officer, Director, Promoter)in

BoardFred Eshelman(Director)inDaniel J Ricca(Director, Promoter)Ebrahim Versi(Director, Promoter)

Co-investorsEshelman Ventures, LLC

DTx Pharmadtxpharma.com in 𝕏acquired by Novartis

The page presented is corporate content for Novartis, a pharmaceutical company that develops medicines across areas such as multiple sclerosis, cardiovascular disease, and oncology.

BiotechHealthtechSan Diego, US

Arthur T Suckow(Executive Officer)in Arthur Suckow, Ph.D.(Founder)in

Co-investorsAccess Biotechnology ExSight Ventures Janus Henderson Investors

Dynelectrodynelectro.com

Dynelectro commercializes solid oxide electrolysis (SOEC) systems for industrial hydrogen production and energy storage, with modular platforms scaling from 250 kW to multi-megawatt capacity.

CleantechDeep TechEnergyHardware

Søren Højgaard Jensen in

Co-investorsThe Footprint Firm PSV Vsquared Ventures Yara Growth Ventures

Electra Therapeuticselectra-therapeutics.com inOct 2025

Electra Therapeutics develops antibody therapeutics targeting Signal Regulatory Protein (SIRP) for immunological diseases and cancer treatment.

BiotechHealthtechMedical DevicesSouth San Francisco, US

Adam Rosenthal(Co-founder and former CEO; Director)inQuehuong (Kathy) Dong, Pharm.D.(Executive Officer, Director)Kathy Dong(President, Chief Executive Officer and Director)in

BoardBeth Seidenberg, M.D.(Director)Thomas Geninatti, Ph.D.(Director)Carl Gordon, Ph.D.(Director)

Co-investorsOrbiMed Westlake Village BioPartners Kleiner Perkins NVIDIA

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

ADRxAerovate TherapeuticsAntera Therapeutics Calimmune Convergent Therapeutics DiCE Molecules Holdings Freenome Holdings Lantos Technologies Lonestar Medicines Memento Medicines NanoMosaic Nature's Toolbox Sojournix Solstice Oncology Superluminal Medicines Typewriter Therapeutics Vaxess Technologies, Inc.89BioAavantiBioAcumen PharmaceuticalsAdagio TxAlchemabAliada TherapeuticsAmbros TherapeuticsAmplifier TherapeuticsAperion LabsArtiosAset Therapeutics AveXis Bellicum Pharmaceuticals Braeburn PharmaceuticalscAMPfield TherapeuticsCanbridge PharmaceuticalsCarmot TherapeuticsCerebral TherapeuticsClementiaClementiapharmaCoherusCollegiumConvergent TxConveyor TherapeuticsCortica CareCorxelCytekDay OneDiagonal TherapeuticsDiceDicernaDimensionEdgewiseEidos TherapeuticsElektrofi

Browse all 353 investments with full details →

▶153 more tracked companies

Element BiosciencesEmergence TherapeuticsEmpaticaEnara BioEverest MedicinesEvodia BioEvodiaBio Expansion TherapeuticsExpedition TherapeuticsEyconis Familiarmachines Farcast Forge BiologicsFormaForward TherapeuticsFrontier MedicinesGaleraGameto GentiBio GIVAX Global Blood Therapeutics Halda Halda TherapeuticsHemaBHilleVax IDRx IDRX ILiAD Biotechnologies Imbria Imbria PharmaceuticalsInfinimmuneInflaRx Inhibikase Therapeutics InhibrxInnoventricInozymeInterius BioInterius BioTherapeutics IO Biotech iTeos Therapeutics Ivantis IncJanuxJnana TherapeuticsJunoKalvista KaryopharmKinnateKinnate Biopharma KolomaLegend BioLenzLifeMineLumenaLusaris TherapeuticsLyraMagenta MedicalMarianaMariana OncologyMBXMementoMerus Metagenomi MetseraMineralysMMI MicroModerna NapiGen Nava Navigator Medicines New Equilibrium Biosciences NexCure Nextop NiKang Therapeutics Nimbus NimbusNimbus TherapeuticsNivalisNorthLinks Bio NucleixObsidian TherapeuticsOcelot BioOllinOncologyOptivoltOrchardPAhR TherapeuticsPandionPelotonPharmaPhathomPinnacle MedicinesPlantiblePluton BioPMV PharmaPoint BiopharmaPoplar TherapeuticsPrevailPrevail TherapeuticsProfound BioProtagonistQuellis Biosciences Ra Pharmaceuticals Radence Reframe SystemsRivus PharmaSatsumaSatsuma Pharmaceuticals Seagen Secretome Therapeutics SeLux Diagnostics, Inc.Serapha BioShockwaveSidera Bio Sierra Oncology Silverback Therapeutics Slate Medicines Somatus Sortera Technologies Sparrow Pharma Star TherapeuticsStokeStylus Medicine Summation BioSuperluminalSynapticureSynthego Synthekine Synthorx T-Knife T2 BiosystemsTaris BiomedicalTassoTenayaTeraPore Technologies Terremotobio terrestrial Thriveworks Topl (Now Plasma)Torl BioTrace NeuroscienceTscanTScan TherapeuticsTyraVentus Ventus Therapeutics Verdiva Bio Verve Therapeutics ViaCyte VitriVaxVividionWhiteSwell Windward Windward Bio

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.

Exits · 102

67 IPOs · 35 acquisitions · showing 79

FreenomeNASDAQ: FRNMSionnatxNASDAQ: SIONMineralys TherapeuticsNASDAQ: MLYSSpero TherapeuticsNASDAQ: SPROWave Life SciencesNASDAQ: WVEAclaris TherapeuticsNASDAQ: ACRSAdagio MedicalNASDAQ: ADGMAdagio Medical HoldingsNASDAQ: ADGMAdagio TherapeuticsNASDAQ: IVVDAeglea BiotherapeuticsNASDAQ: SYREAgenusNASDAQ: AGENAktis OncologyNASDAQ: AKTSAN2 TherapeuticsNASDAQ: ANTXApogee TherapeuticsNASDAQ: APGEArcutisNASDAQ: ARQTArvinas Holding Co. LLCNASDAQ: ARVNAtea PharmaceuticalsNASDAQ: AVIRBicara TherapeuticsNASDAQ: BCAXBioAge LabsNASDAQ: BIOABiohavenNYSE: BHVNBlack Diamond Therapeutics, IncNASDAQ: BDTXBolt BiotherapeuticsNASDAQ: BOLTBoundless BioNASDAQ: BOLDC4 TherapeuticsNASDAQ: CCCCCentury Therapeutics, Inc.NASDAQ: IPSCCeribellNASDAQ: CBLLCG OncologyNASDAQ: CGONClimbbioNASDAQ: CLYMCollegium PharmaceuticalNASDAQ: COLLConnect BiopharmaNASDAQ: CNTBCrineticsNASDAQ: CRNXCytek BiosciencesNASDAQ: CTKBDamora TherapeuticsNASDAQ: DMRADesigntxNASDAQ: DSGNDiffusion PharmaceuticalsNASDAQ: CRVODyne TherapeuticsNASDAQ: DYNEliem TherapeuticsNASDAQ: CLYMEnliven TherapeuticsNASDAQ: ELVNGH ResearchNASDAQ: GHRSHemab TherapeuticsNASDAQ: COAGImaraNASDAQ: ELVNInvivydNASDAQ: IVVDKALA BIONASDAQ: KALAMonopar TherapeuticsNASDAQ: MNPRNateraNASDAQ: NTRANkarta, Inc.NASDAQ: NKTXOlemaNASDAQ: OLMAParabilis MedicinesNASDAQ: PBLSPepGenNASDAQ: PEPGPrecision BioSciencesNASDAQ: DTILProtagonist TherapeuticsNASDAQ: PTGXProthenaNASDAQ: PRTAPyxis OncologyNASDAQ: PYXSRani TherapeuticsNASDAQ: RANIRani Therapeutics HoldingsNASDAQ: RANIRelmada TherapeuticsNASDAQ: RLMDRxsightNASDAQ: RXSTScribe TherapeuticsNASDAQ: SCTXScynexisNASDAQ: SCYXSeres TherapeuticsNASDAQ: MCRBSolid BiosciencesNASDAQ: SLDBSpyglass PharmaNASDAQ: SGPSutroVaxNASDAQ: PCVXTYRA BiosciencesNASDAQ: TYRAVaxcyteNASDAQ: PCVXVor BiopharmaNASDAQ: VORXilio TherapeuticsNASDAQ: XLOAerovate Therapeuticsacq. by Jade BiosciencesCalimmuneacq. by CSL Behring89Bioacq. by RocheAliada Therapeuticsacq. by AbbVieAmbros Therapeuticsacq. by Werewolf TherapeuticsBellicum Pharmaceuticalsacq. by The University of Texas MD Anderson Cancer CenterBluejay Therapeuticsacq. by Mirum PharmaceuticalsDay Oneacq. by ServierDicernaacq. by Novo NordiskDTx Pharmaacq. by NovartisEidos Therapeuticsacq. by BridgeBio PharmaElektrofiacq. by Halozyme Therapeutics

Portfolio news

latest coverage across their companies

5 Stocks, 5 Different Industries, 1 Thing in Common: Reliable Income - AOL

Apogee Therapeutics · aol.com · Sep 18, 2026

Circle Pharma Raises $92.5M in Series E Funding - NewsBreak

Pharma · newsbreak.com · Sep 17, 2026

3 Clinical-Stage Cancer Stocks With Pristine Balance Sheets - Simply Wall St News

Oncology · simplywall.st · Sep 16, 2026

Damora Therapeutics: Potential Payday Is A Long Way Off (NASDAQ:DMRA) | Seeking Alpha

Damora Therapeutics · seekingalpha.com · Sep 15, 2026

InflaRx at H.C. Wainwright conference: renal pivot takes center stage By Investing.com

InflaRx · investing.com · Sep 14, 2026

Stifel cuts Olema Pharmaceuticals price target on trial concerns By Investing.com

Olema · investing.com · Sep 14, 2026

Your Weekly Biotech News Fix | Ep. 1078 - BowTiedBiotech

Karyopharm · bowtiedbiotech.substack.com · Sep 12, 2026

Ceribell senior VP sells $224,451 of company stock By Investing.com

Ceribell · investing.com · Sep 11, 2026

IPO stake values · per SEC filings · 25

Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.

Company	Owned	IPO price	At IPO	Stake value
Sionnatx	21.9%	$18.00	Feb 2025	$167.8M
Climbbio	51.9%	$12.50	Aug 2021	$164.4M
Eliem Therapeutics	51.9%	$12.50	Aug 2021	$164.4M
Parabilis Medicines	6.5%	$20.00	Jun 2026	$154.9M
Vor Biopharma	22.2%	$18.00	Feb 2021	$142.2M
Apogee Therapeutics	3.4%	$62.00	Mar 2024	$122.6M
Cytek Biosciences	5.1%	$17.00	Jul 2021	$113.2M
TYRA Biosciences	14.6%	$16.00	Sep 2021	$95.8M
Bicara Therapeutics	9.9%	$18.00	Sep 2024	$92.2M
Hemab Therapeutics	10.9%	$18.00	May 2026	$87.1M
Wave Life Sciences	24.9%	$16.00	Nov 2015	$83.4M
Adagio Therapeutics	4.4%	$17.00	Aug 2021	$81.6M
Invivyd	4.4%	$17.00	Aug 2021	$81.6M
Dyne Therapeutics	5.5%	$28.00	Jan 2021	$78.5M
Spyglass Pharma	13.6%	$16.00	Feb 2026	$69.3M
AN2 Therapeutics	19.6%	$15.00	Mar 2022	$55M
Vaxcyte	6.2%	$16.00	Jun 2020	$47.8M
SutroVax	6.2%	$16.00	Jun 2020	$47.8M
Bolt Biotherapeutics	6.9%	$20.00	Feb 2021	$47.6M
Solid Biosciences	7.8%	$16.00	Jan 2018	$43M
Prothena	7.8%	$22.00	Oct 2013	$36.3M
Olema	4.5%	$19.00	Nov 2020	$32.8M
Collegium Pharmaceutical	6.6%	$20.00	Jan 2016	$30.9M
Mineralys Therapeutics	4.9%	$16.00	Feb 2023	$30.9M
Black Diamond Therapeutics, Inc	4.6%	$19.00	Jan 2020	$30.2M

Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).

Public market activity · per SEC filings

what is this? ⓘ

SC 13D/A filingSC 13D/A

Disclosed stake · filed Dec 2018

view filing ↗

SC 13G/A filingSC 13G/A